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 Synopsis 
 
 This thesis sought to investigate how systemic lipids may contribute to the 
adipocyte derived inflammatory response and highlight how the adipocyte’s function 
can alter in different metabolic states which could contribute to the pathogenesis of 
type 2 diabetes mellitus (T2DM) and cardiovascular risk. Specifically, this thesis 
firstly examined the inflammatory nature of lipoprotein-associated phospholipase A2 
(LpPLA2), a member of the phospholipase A2 super family of enzymes which 
previously has been shown to enhance Ox-LDL production in foam cells during 
arterial inflammation contributing to coronary artery disease. Therefore initial studies 
sought to (1) characterise PLA2 isoforms in lean, obese, T2DM abdominal 
subcutaneous (AbdSc) and omental (Om) in human adipose tissue (AT); (2) evaluate 
the role of lipids and inflammatory markers on circulating LpPLA2, and (3) 
determine the in vitro regulation of LpPLA2 in human adipocytes by its influence on 
LDL and Ox-LDL.  
 AT and sera from lean, overweight, obese and T2DM subjects were taken. 
PLA2 gene expression was determined by microarray, RT-PCR and Western Blot. 
Associations between circulating LpPLA2 and metabolic parameters were 
investigated. The human adipocyte cell line, Chub-S7, was used to assess the effects 
of oxidized LDL (Ox-LDL) and LDL on PLA2 expression. 
LpPLA2 mRNA levels were higher in AbdSc AT than Om AT in obesity by 2-fold 
(P<0.05). The cPLA2 protein expression increased with obesity in AbdSc AT 
(P<0.01). T2DM showed increased LpPLA2 mRNA levels in AbdSc (P<0.001) and 
Om AT (P<0.01). Serum LpPLA2 showed positive correlations with cholesterol, 
TG, LDL, endotoxin and Ox-LDL (P<0.001) in non-diabetic subjects and with Ox-
  
 
 
LDL (P<0.001), LDL (P<0.01) and cholesterol (P<0.05) in T2DM. In differentiated 
pre-adipocytes, activation of LpPLA2 protein expression was noted in response to 
LDL and Ox-LDL (P<0.001). The adipocyte appeared to be an active source of 
LpPLA2, altered by fat depot and metabolic state, with LpPLA2 protein expression 
induced by LDL and Ox-LDL, in vitro. Increased LpPLA2 protein from the 
adipocyte in obesity and/or T2DM could contribute to raise circulating Ox-LDL, as 
noted in other studies as well with increasing adiposity, which promotes further 
inflammation and atherosclerotic risk.  
 Through the development of these current studies it appeared that how the 
adipocyte managed lipids was important to how the adipocyte may induce an 
inflammatory response and pathogenic factors. Therefore subsequent studies 
investigated how the change in metabolic state such as those derived in T2DM 
patients that undergo bariatric surgery may not necessarily reverse their 
inflammatory response. Previous studies from the team have shown that lipids may 
induce an innate immune response via toll like receptor (TLR) activation therefore 
subsequent investigations sought to consider the potential role of triglycerides (TG) 
as another mediator of inflammation. As such studies examined the specific impact 
of TG changes, pre- and post-bariatric surgery, on TLR expression in ex vivo AT and 
the in vitro effects of triglyceride rich lipoprotein (VLDL), on TLR expression in 
isolated human differentiated pre-adipocytes.  Serum and AT was taken from a 
cohort of Obese, T2DM, female subjects prior to bariatric surgery and 6 months post-
surgery. Human differentiated pre-adipocyte Chub S7 cells were again used to 
examine transcriptional effects of VLDL on TLR expression.  
 Following surgical intervention, BMI (P<0.001), blood glucose (P<0.001), 
insulin (P<0.001), HOMA-IR (P<0.001), TG (P<0.05), Cholesterol (P<0.001) and 
  
 
 
LDL-cholesterol (P<0.05) were significantly improved. There was a significant 
reduction in TLR-4 mRNA post-surgery (P<0.01) irrespective of surgery type. It was 
also noted that subjects with the greatest drop (55.5% reduction) in TGs post-surgery 
(P<0.001) showed a significant correlated reduction in TLR4 mRNA expression 
(P<0.001). Whilst the in vitro treatment of differentiated Chub S7 cells highlighted 
VLDL induced TLR 4 mRNA expression (P<0.05) suggesting the inflammatory 
impact of lipids on adipocytes. These studies further highlighted that the reduction in 
AT inflammation appears dependent on how successfully subjects reduce their serum 
triglyceride, which appears supported by the in vitro findings. These studies suggest 
that bariatric surgery lead to metabolic improvement with weight loss, whilst dietary 
intervention is still required to ensure TGs reduce to reduce inflammation. 
 Taken together, these studies and thesis highlight the diverse nature of lipids 
and their interaction with the adipocyte to impact on their inflammatory response. 
These data also highlight the importance to maintain a good systemic lipid profile 
low in TG to reduce adipocyte induced inflammation and that AT may represent an 
important therapeutic target to reduce inflammation, atherosclerotic risk and 
development of metabolic complications. 
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1.1 Obesity 
1.1.1 Definition and causes of obesity  
Obesity is a condition of energy imbalance between energy intake and energy 
expenditure, leading to hypertrophy (increase of cell size) and hyperplasia (increase 
of cell number) of adipose tissue. The increased fat mass can be reflected by simple 
anthropometric measures such as Body Mass Index (BMI), waist circumference 
(WC) and waist to hip ratio (WHR). BMI is calculated through the division of weight 
in kilograms by the square of height in meters. BMI over 30 has been classified as 
obesity, according to World Health Organization (WHO) international of 
classification obesity (Table 1.1). BMI is a powerful gender independent predictor of 
obesity related metabolic diseases such as hypertension, lipid profiles abnormalities, 
T2DM and cardiovascular diseases (Gierach, Gierach, Ewertowska, Arndt, & Junik, 
2014).  
In addition, fat accumulation site is also one of the parameters that predict the 
risk of obesity complications. Increased fat expansion around abdomen 
(subcutaneous and omental AT), known as central obesity, showed stronger 
correlations with obesity related diseases compared to the fat accumulation ino the 
lower part of body (hip, tight). Abdominal or visceral fat accumulation can be 
estimated by waist circumference (WC) and waist to hip ration (WHR). With the 
same BMI, subjects who had higher WC showed the higher risk of obesity related 
metabolic diseases. Several studies suggested that WC and WHR measurements are 
better predictors for obesity related metabolic diseases than BMI (Elbassuoni, 2013; 
Jayawardana, Ranasinghe, Sheriff, Matthews, & Katulanda, 2013; Jing et al., 2012). 
However,  some studies suggested that WHR was not better than BMI in CVD 
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prediction in Northern Europe population (Goh, Dhaliwal, Welborn, Lee, & Della, 
2014), whist WC is a better predictor than WHR and BMI in Asian women (Choi, 
2011; Singhal, Mathur, & Pathak, 2011). Thus, the WC and WHR cut points are not 
appropriated across worldwide. Unfortunately, to date, there are still no standardized 
criteria for each specific ethnics.  
Besides ethnicity, fat distribution is also influenced by gender through 
androgen metabolism in adipose tissue, resulting in higher prevalence of central 
obesity in male than female (De Maddalena, Vodo, Petroni, & Aloisi, 2012; O'Reilly, 
House, & Tomlinson, 2014).  Studies in menopause women confirmed that fat 
distribution was shifted to abdomen in subjects with decreased estrogen and 
increased androgens (Lizcano & Guzmán, 2014; Vaidya et al., 2012). Environmental 
factors such as physical activity, food consumption, medications and illnesses 
contribute to obesity as well. High carbohydrate and fat composition of diets induced 
adipose tissue expansion (Cummins et al., 2014). Some medications used in T2DM 
treatments such as insulin (Home et al., 2014) and sulfonylurea (Thulé & Umpierrez, 
2014) have been reported to correlate with weight gain.  
Although, anthropometric measures such as BMI, WC and WHR have 
limitations in obesity related disease prediction due to ethnicity and gender, they are 
simple and useful tools for both individuals and health care professionals to be aware 
of obesity in order to prevent the early onset of obesity related diseases such as 
T2DM, hypertension, dyslipidemia and cardiovascular diseases (Abdullah et al., 
2012). 
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Table 1. 2 Obesity Classification. BMI criteria for obesity diagnosis according to 
WHO, NHLBI and WPRO. 
 
WHO 
(2000) 
Classification 
 
NHLBI 
(1998) 
Classification 
 
BMI 
(kg/m
2
) 
 
WPRO 
(2000) 
Classification 
 
BMI 
(Kg/m
2
) 
 
Underweight 
Normal range 
Pre-obese 
Obese I 
Obese II 
Obese III 
 
Underweight 
Normal range 
overweight 
Obese I 
Obese II 
Obese III 
 
18.5 
18.5-24.9 
25-29.5 
30-34.9 
35-39.9 
40 
 
Underweight 
Normal range 
Overweight at risk 
Obese I 
Obese II 
 
 
18.5 
18.5-22.9 
23-24.9 
25-29.9 
30 
Adapted from (Anuurad et al., 2003) 
1.1.2 Epidemic of Obesity  
Overweight and obesity is the global epidemic which the prevalence has been 
dramatically increased by 27.5% for adults and 47.1% for children during the past 
few decades (Kassebaum et al., 2014; Ng et al., 2014). It has been estimated by 
WHO in 2008 that obesity reached 35 % of population worldwide. The prevalence of 
obesity is rising all across the world. The highest obesity prevalence is in America 
with 35.7% for adults and 16.9% of children and it has been forecasted to increase by 
51% in 2030 (Finkelstein et al., 2012; Padwal, 2014). Interestingly, Asian 
populations have also shown the drastically increasing number of overweight and 
obese. Studies in Japanese and Chinese populations, the combined prevalence of 
overweight and obese dramatically rise by 46% in Japan and 414% in China within 
20 years periods (Collaboration, 2007).  
 It must be noted that the increased risk of complications related to obesity is 
ethnic specific. Asian populations seem to develop obesity related diseases at much 
lower BMI than western populations (Shiwaku et al., 2004; J. J. Yang, Shiwaku, 
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Nabika, Masuda, & Kobayashi, 2007). Thus, the Regional Office for Western Pacific 
Region of WHO and the International Obesity Task Force of WHO (WPRO) has 
proposed in 2000 the new specific criteria for overweight and obesity classification 
for Asian populations. According to this guideline, BMI over 25 is classified as 
obesity (Table 1.1). Increasing numbers of studies have been supported that the 
WPRO criteria was more sensitive to reflect the obesity status in Asian populations 
(Anuurad et al., 2003; Jitnarin et al., 2011; Shiwaku et al., 2004). Thus, the numbers 
of overweight and obese patients were unsurprisingly much higher when the WPRO 
criteria were used as the cut points (Jitnarin et al., 2011).  
1.1.3 Obesity interventions 
 The increasing prevalence of obesity closely associates with the high risk of 
chronic diseases such as T2DM, cardiovascular disease and cancer. Obesity is 
considered as a major causation of hypertension and T2DM and prevalence of T2DM 
is also associated with BMI  (Colosia, Palencia, & Khan, 2013). Obesity with T2DM   
is associated with lipid profile abnormality (Brea et al., 2011). Data from large 
cohort study indicated that high BMI with increased WHR increases mortality as 
well as risk of cardiovascular diseases (Borrell & Samuel, 2014; Myint, Kwok, 
Luben, Wareham, & Khaw, 2014). Thus, weight managements are essential for the 
health care of obesity. The obesity interventions are mainly involved with two 
approaches; the reduction of energy intake and induction of energy expenditures 
(Clapham & Arch, 2011). However, it is also suggested that intensive treatment of 
T2DM by using drugs alone did not improved prognosis but eventually increased 
mortality (Gorgojo Martínez, 2011).  Weight control including modification of diet, 
increasing physical activity has shown to significantly improve CVD risk. It has been 
  
6 
 
reported that 10% weight loss reduced prevalence of T2DM for 30% and CVD for 
20% (McQuigg et al., 2008). However, life style changes are difficult. It has been 
shown that almost 50% of participants failed to maintain weight (Barte et al., 2010).  
1.1.3.1 Bariatric surgery 
 Bariatric surgery is recommended in T2DM patients with BMI  35 Kg/m2, 
especially for patients with insufficient glycemic control (Buchwald, Ikramuddin, 
Dorman, Schone, & Dixon, 2011). The bariatric operation is classified into three 
major techniques; (1) Restrictive techniques which reduce the stomach size in order 
to reduce food digestion e.g. adjustable gastric bands, vertical banded gastroplasty 
and sleeve gastractomy (SG). (2) Malabsorptive type surgery which reduces food 
intake and absorption by cutting off some part of stomach, intestine and pancreas and 
creating bypass between stomach and intestine e.g. biliopancreatic diversion (BPD) 
and jejunoileal bypass. (3) Mix technique e.g. biliopancreatic diversion with 
duodenal switch (BPD-DS) and Roux-en-Y gastric bypass (RYGB) (Figure1.1.3.1.1) 
(Ashrafian & le Roux, 2009).  
 Bariatric surgery generally reduced visceral fat mass. Since chronic enlarged 
adipocytes mediate inflammation and insulin resistance, acute reduction of 
pathogenic fat mass consequently reduces circulating inflammatory cytokines such as 
Il-6, TNF and CRP (Lasselin et al., 2014; Viana et al., 2013) and increases insulin 
sensitivity (Mor, Tabone, Omotosho, & Torquati, 2014). Lipolysis is inhibited during 
weight loss, resulting in reduction of circulating free fatty acid (Campos et al., 2014; 
Mor et al., 2014). In addition, angiogenesis in AT is gradually reduces after surgery 
due to the reduction of vascular endothelial growth factor-A (García de la Torre et 
al., 2008; Ledoux et al., 2008). Acute caloric restriction directly effects lipid profile, 
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reducing cholesterol, triglycerides and LDL. It has been reported that several anti-
inflammation adipokine such as adiponectin and IL-10 increase during weight loss 
(Hosseinzadeh-Attar, Golpaie, Janani, & Derakhshanian, 2013; McCormick, 2013).  
Bariatric surgery directly affects gut hormones. Different types of surgery 
influence different gut hormone production. The gastric bypass which shortens the 
delivery of nutrients to distal bowel increases the production of peptide tyrosine-
tyrosine (PYY), oxyntomodulin (OXM) and Gastric Inhibitory Peptide (GIP), 
reducing food intake. 
 
 
Figure 1.1.3.1.1  Bariatric procedures and their effects on gut hormones. 
Ghr; Ghrelin (active appetite hormone), GLP-1; glucagon-like peptide-1 (promote 
energy storage in AT), PYY; peptide tyrosine-tyrosine (decrease food intake), OXM; 
oxyntomodulin (decrease food intake), GIP; Glucose dependent insulinotropic 
peptide or Gastric Inhibitory Peptide (decrease food intake). (Tharakan, Tan, & 
Bloom, 2011).  
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1.1.4 Metabolically healthy obesity 
Although the strong association of obesity and its related diseases has been 
extensively reported in general population, numerous of studied reported that the 
development of obesity related chronic diseases does not always occur in some cases. 
This phenotype was termed as Metabolic Healthy Obesity (MHO) which is defined 
as an obesity (BMI>30 Kg/m
2
) with no metabolic diseases such as hypertension, 
dyslipidemia and impaired glycemic control. With these criteria, increasing numbers 
of studies indicated that MHO phenotype was associated with the lower risk of 
T2DM compared to non-MHO phenotype (Hinnouho et al., 2014; Rhee et al., 2014). 
However, to date, there are no standardized criteria to distinguish between MHO and 
non-MHO and no evidence to state that MHO is not risky. 
Interestingly, difference between MHO and non-MHO seems to strongly 
involve sub-clinical inflammation. MHO as well as non-obese showed the lower 
levels of complement component 3, C-reactive protein, TNF-α, IL-6, and 
plasminogen activator inhibitor-1and white blood cell count  compared to non-MHO 
(Koster et al., 2010; Phillips & Perry, 2013). In addition, with the same BMI, non-
MHO with high circulating inflammatory adipokines significantly associated with 
visceral obesity (Koster et al., 2010; Phillips & Perry, 2013; van Beek et al., 2014). 
Thus, development of obesity related metabolic diseases is most likely contributed 
by adipose tissue inflammation rather than BMI alone and routine measurement of 
anthropometry along with adipose tissue inflammatory might be helpful for diagnosis 
and treatment in obesity and metabolic diseases.   
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1.2 Adipose tissue as a contributor to metabolic dysfunction 
1.2.1 Abdominal adipose tissue expansion in obesity 
Abdominal adipose tissue (Abd AT) is categorized according to fat tissue 
compartment into 2 depots; abdominal subcutaneous AT and visceral or omental AT. 
AT is an important reversible storage pool which firstly responds to chronic excess 
energy. Excess energy stores mostly in the form of triglyceride (TG) via lipogenesis 
by adipocytes. Increased lipogenesis causes lipid accumulation, enlarging adipocyte 
size (AT hypertrophy). Besides triglyceride accumulation, pre-adipocyte also 
responds to energy excess via cell proliferation and differentiation, resulting in 
increasing numbers of mature adipocytes (AT hyperplasia) (Proença et al., 2014; Q. 
A. Wang, Tao, Gupta, & Scherer, 2013). Previous studies showed that obese subjects 
with BMI greater than 30 kg/m
2
 have large fat cell sizes, compared to lean control 
subjects (Heinonen et al., 2014; van Harmelen et al., 2003). Excessive AT 
hypertrophy subsequently mediates adipocyte deregulation, increasing the production 
of non esterified fatty acids (NEFAs) and pro-inflammatory cytokines (e.g. TNF, 
IL-6, IL-1) release which were been reported as a cause of insulin resistance. In 
studies in human adipose tissue, TNF expression was correlated with BMI, 
percentage of body fat and hyperinsulinaemia, whereas weight loss decreased TNF 
expression (Rajkovic et al., 2014). Similarly, increased circulating IL-6 level is 
observed in obese and insulin resistant subjects (Bordon, 2014; Rajkovic et al., 
2014). The significant correlation between serum free fatty acid and BMI as well as 
insulin resistance was also reported (Frohnert et al., 2013) and a study in C57Bl6/J 
mice indicated that high fat diet induced hepatic insulin resistance (Wiedemann, 
Wueest, Item, Schoenle, & Konrad, 2013).   
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Enlargement of adipocyte differs between AT depots and the enlarged size of 
the cell induced by excessive nutrition indicates cellular dysfunction. Large 
adipocytes were more profound in Om AT compared to Abd Sc AT.  The different 
AT depots also exhibit differences in protein expression as well as cellular 
responsiveness. Expression of adipose genes such as adiponectin (Rahmouni, Mark, 
Haynes, & Sigmund, 2004) as well as pro-inflammatory cytokines (plasminogen 
activator inhibitor-1 (PAI-1) (Rahmouni et al., 2004), IL8 (Bruun et al., 2004) and 
IL-6 (Fried, Bunkin, & Greenberg, 1998) were higher in Om AT. Leptin is 
preferentially secreted in Sc AT (Schoof et al., 2004). Moreover, Sc AT is considered 
to be more sensitive to insulin than Om AT (Bolinder, Kager, Ostman, & Arner, 
1983), whilst the Om AT suppresses about 50% of glucose uptake after insulin 
treatment (Stolic et al., 2002). Since the venous blood of Om AT flows through 
hepatic portal vain, the increasing secretions of pro-inflammatory adipokines are 
directly drained to circulation, leading to systemic inflammation.  
Like other organ, AT contains not only adipocyte but also a population of 
cells of the innate immune system such as macrophage and lymphocyte. It is 
suggested that macrophage infiltration in AT is strongly associated with chronic, low 
grade inflammation in obesity (McNelis & Olefsky, 2014). Several studies reported 
that the number of macrophages was more in Om AT than Sc AT and induced insulin 
resistance (Harlev et al., 2014). Increasing macrophage infiltration is directly 
associated with the higher expression of calling signal, the monocyte attractant 
protein1 (MCP1), in Om AT (Harman-Boehm et al., 2007). In addition, impaired 
angiogenesis in disproportionate adipocyte hypertrophy in Om AT causes tissue 
hypoxia (Elias et al., 2012), leading to adipocyte apoptosis which potentially induces 
macrophage infiltration for death cell clearance.   
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1.2.2 Lipid metabolism and adiposity  
 Dietary fats are digested into monoglycerides, free fatty acids and 
cholesterols by gastric and pancreatic lipase. These digested insoluble products are 
emulsified by bile salt and absorbed into intestine. In enterocytes, triglycerides are 
re-synthesized and assembled with cholesterol ester and protein to form 
chylomicrons. Chylomicron particles are released into the circulation and hydrolyzed 
to release free fatty by lipoprotein lipase (LPL) in peripheral tissue such as AT and 
muscle and circulated until taken by the liver. Free fatty acids as well as cholesterol 
esters packed inside chylomicron remnant serves as precursors for liver to synthesize 
necessary lipids.  
 Liver re-synthesizes TG, using free fatty acids as precursors via hepatic 
lipogenesis, and delivers with cholesterol esters and other lipids by packing into very 
low density lipoprotein (VLDL) particles. Major lipids containing in VLDL particle 
is fatty acids, follows by cholesterol esters (Figure 1.2.2.1). Similar to chylomicrons, 
VLDL particles deliver fatty acids to adipose tissue, muscle and other tissue via LPL 
activity and become gradually smaller, resulting in a higher density lipoprotein 
compared to VLDL, termed low density lipoprotein (LDL). LDL particles are re-
uptake via LDL receptors in liver. The remaining lipids (mostly is cholesterol) in 
LDL particle are stored in liver cells (Proença et al., 2014). In high fat dietary, liver 
control circulating LDL level and lipid storage by reducing synthesis of cholesterol 
as well as LDL receptor. Reduction of LDL receptor prolongs circulation of LDL, 
leading to high level of serum LDL. Prolonged LDL in circulation is susceptible for 
oxidation of both protein and lipid in LDL particle. Thus, long term high fat dietary 
as well as high serum LDL has been reported to correlate with increased oxidized 
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LDL (ox-LDL) (Figure 1.2.2.2). ox-LDL is recognized and uptake by macrophage 
via scavenging receptor. 
 
 
 
Figure 1.2.2.1 Classification of circulating lipoprotein. Lipoproteins are classified 
according to their density separated by ultracentrifugation into Chylomicron (CM), 
Very low density lipoprotein (VLDL), Low density lipoprotein (LDL). (Curcio, 
Johnson, Huang, & Rudolf, 2009) 
 
 
 
 HDL (High density lipoprotein) is originally synthesized in liver as a nascent 
HDL. It is considered as a good lipoprotein as it helps to “clean up” cholesterol from 
circulation. Circulating HDL uptake and esterifies cholesterol from peripheral tissue 
and other lipoproteins by lecithin-cholesterol acyltransferase (LCAT). HDL with 
cholerterol accumulation returns to liver via Scavenger Receptor class B type 1 (SR-
B1). High serum HDL is associated with improvement of cardiovascular risk 
(Martin, Jones, & Toth, 2014).  
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Figure 1.2.2.2 Overview of lipoprotein metabolism. Exogenous dietary fat is 
absorbed  and deliver as chylomicron to liver. Liver is aprimary organ that 
synthesizes TG and cholesterol. Lipid productions are circulated in the form of Very 
low density lipoprotein (VLDL) which gradually deliver lipids to peripheral tissue by 
lipoprotein lipase (LPL) activity. VLDL becomes intermediate low density 
lipoprotein (IDL), low density lipoprotein (LDL) and uptake by liver via LDL 
receptor. Nascent HDL is synthesized by liver and delivered to obtain cholesterol and 
TG from tissue. Nascent HDL is increased its size because of lipid uptake, becoming 
HDL3 and HDL2. HDL is uptake by liver. (Giannarelli, Klein, & Badimon, 2011) 
 
1.2.3 Lipogenesis and lipolysis in adipocyte 
 Free fatty acids delivered by both chylomicrons and lipoproteins; VLDL and 
LDL, are taken up by adipocytes by fatty acid transporter protein (FATP) and store 
as TG via TG re-synthesis (lipogenesis) in liver. In adipocytes, free fatty acids 
convert into fatty acyl-CoA and re-synthesize TG via lipogenesis (Figure 1.2.3.1). 
Key enzymes in lipogenesis are transcriptional controlled by Sterol Response 
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Element Binding Protein 1c (SREBP1c) and Carbohydrate Response Element 
Binding Protein (ChREBP) (Iizuka, 2013). Under insulin resistant state, high 
carbohydrate and fat diet induced SREBP1c expression, leading to fat deposition in 
responsive organs, especially AT and liver (Czech, Tencerova, Pedersen, & Aouadi, 
2013). Up-regulation of ChREBP in liver is associated with insulin resistance, 
induces hepatic steatosis (Iizuka & Horikawa, 2008). Unlike liver, increased 
ChREBP in adipose tissue induces insulin sensitivity (Benhamed, Poupeau, & Postic, 
2013). This data indicates that activation of lipogenesis in adipose tissue has 
metabolic benefits.    
 In contrast to lipogenesis, lipolysis is the process that intracellular TGs are 
hydrolyzed into NEFA and delivered to the circulation (Zaidi et al., 2013). This 
process is positively controlled by several hormones including, hormone-sensitive 
lipase (HSL) and catecholamine and negatively controlled by insulin (Frühbeck, 
Méndez-Giménez, Fernández-Formoso, Fernández, & Rodríguez, 2014). It is wildly 
known that high level of NEFA is observed in obese and T2DM subjects, indicating 
that lipolysis is increased in obesity and the increased rate of lipolysis is correlated 
with enlarged of adipocyte size (Lambert, Ramos-Roman, Browning, & Parks, 
2014). In addition, hepertrophy of AT (enlarged cell size) is active in lipolysis 
(Michaud et al., 2014) and less susceptible to insulin (Zhai et al., 2010). Thus, 
increased fat mass in omental AT can be a season of increased free fatty acids in 
obesity.  
 In addition, several adipokines also affect lipid metabolism. Adiponectin 
increases NEFA uptake and -oxidation in muscle cell, reducing circulating NEFA 
(Maeda et al., 2002; Terazawa-Watanabe, Tsuboi, Fukuo, & Kazumi, 2014). In 
contrast, TNF reduced free fatty acid uptake and increases lipolysis, leading to 
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increased level of free fatty acid in circulation (Chen, Xun, Chen, & Wang, 2009; 
Ryden et al., 2002). IL-6 also has been reported to reduce the LPL activity in adipose 
tissue (Trujillo et al., 2004). Both circulation levels of TNF and IL-6 correlates with 
free fatty acid in obesity.    
 
 
Figure 1.2.3.1 Overview of lipogenesis and lipolysis. In the fasting state, hormone 
sentitive lipase (HSL) is activated by insulin and hydrolyze intracellular TG to 
generate NEFA . NEFA is circulated to serve as an energy fuel of peripheral tissue. 
After meal, NEFA is uptake by LPL activity. The NEFA is re-synthesized into TG, 
stored in AT. (Avram, Avram, & James, 2005)  
 
1.2.4 Inflammation in adipose tissue 
 The mechanism which turns on the inflammation in AT is not clear and 
progression of inflammation is complicated. Adipocyte itself has the ability to secret 
various inflammatory cytokines such as TNF, MCP-1, IL-8and IL-6 as well as anti-
inflammatory cytokines such as adiponectin, leptin and IL-10 (Ohashi, Shibata, 
Murohara, & Ouchi, 2014). Excessive AT hypertrophy and hyperplasia causes 
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adipocyte dysfunction, leading to overproduction of inflammatory and reduction of 
anti-inflammatory adipokines (Lafontan, 2014)(Figure 1.2.4.1).  
Adiponectin is a hormone that is involved in many cellular activities, 
including adipocyte differentiation and muscle cell proliferation. It plays a protective 
role in atherosclerosis and T2DM. Serum level of adiponectin is decreased in 
obesity. Adiponectin treatment improves insulin sensitivity and glycemic control in 
animal models (Yamauchi, Iwabu, Okada-Iwabu, & Kadowaki, 2014).  
Leptin is a satiety hormone that controls dietary intake and benefits to weight 
control by activating energy expenditure. Leptin is correlated with BMI and it is 
increased in obesity (Wilding, 2001).  
Both IL-6 and TNF are increased in obesity and exhibit pro-inflammatory 
as well as pro-atherogenic effects. TNF and IL-6 activated inflammation pathway 
which further impaired the insulin signaling pathway (D. Cai et al., 2005; Makki, 
Froguel, & Wolowczuk, 2013) 
 
Figure 1.2.4.1 Adipose tissue secretion. In adiposity, enlarged adipocyte becomes 
dys-regulation, secreting inflammatory cytokines such as IL-6, TNF ans MCP-1, 
reducing Anti-inflammatory adipokines production and increasing macrophage 
infiltration.  (Capuron & Miller, 2011) 
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   Adipocytes respond to those inflammatory cytokines and metabolic stress 
through various signal transduction pathway such as, the nuclear factor kappa B 
(NFB) and Toll like receptors (TLRs) pathway. Following is the summary of NFB 
and TLR pathway and their roles in adipocyte inflammation and obesity.  
1.2.4.1 IB/NFB pathway 
NFB is a transcription factor protein family consists of 5 subunits member; 
RelA (p65), RelB, c-Rel, NFB1 (p65) and NFB2 (p52). The classical pathway of 
NFB relies on the activation of RelA/p50 NFB dimers, which activity is controlled 
by binding with its inhibitor, IB. Once the cells are activated by stimuli, IB 
subunit is phosphorylated by activated IB kinase (IKK) to release an active 
RelA/p50 NFB complex. The active NFB translocates into nuclear and binds to its 
responsive element to start DNA transcription (Figure 1.2.4.1.1). The alternative 
pathway is to activate RelB/p52 complex which binds to p100 in un-activated cell 
(Razani, Reichardt, & Cheng, 2011).  
 
Figure 1.2.4.1.1 Activation of inflammation via IB/NFB cascade. NFB is 
activated by a range of stimuli such as inflammatory cytokines, immunogenic 
antigen such as CD40 and LMP as well as FFA (Yung & Linch, 2003) 
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Activation of NFB is induced by various stimuli. Cytokines such as TNF, 
IL-6 activate NFB via cytokine receptors, resulting in regulation of insulin 
signaling and cytokines productions (Lee & Lee, 2014). Activation of NFB by high 
fat diet is an important factor that contributes to insulin resistance (Harte et al., 
2013b). Study in IKK knockout mice shows the protective effect of insulin resistant 
developments induced by high fat diet (J. K. Kim et al., 2001). In vitro, incubation 
the L6 muscle cell with palmitate increased NFB p65 and NFB p50 expression 
and induced inflammatory cytokine production  and insulin resistant phenotype 
(Barma et al., 2009).  
Recently, increased serum level of CD40, the protein produced by a range of 
cell types such as T-cell, B-cell, granulocyte and macrophage, was observed in 
patients with obesity (Unek et al., 2010). It is involved in adipose tissue 
inflammation (Missiou et al., 2010). Incubation of CD40 with adipocytes activate 
pro-inflammatory cytokine productions (IL-6, MCP-1, IL-8, and PAI-) via NFB 
activation (Chatzigeorgiou, Phieler, Gebler, Bornstein, & Chavakis, 2013; Missiou et 
al., 2010).      
Lipopolysaccarides activate NFB pathway via Toll like receptor (TLR), 
inducing the innate immune response in various tissue, including adipocyte. TLRs 
family has been reported to express in adipose tissue (Poulain-Godefroy et al., 2010). 
Under normal physiological condition, LPS derives from normal flora in 
gastrointestinal tract, is co-absorbed with fatty acids and release to circulation with 
chylomicrons (Manco, Putignani, & Bottazzo, 2010). In circulation, LPS binds to 
LPS binding protein (LPB), transporting LPS to lipoprotein such as VLDL and LDL. 
It has been reported that LPS level is increased in obesity and T2DM (Creely et al., 
2007; Harte et al., 2010; Harte et al., 2012).  
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1.2.4.2 Toll like receptors 
 Toll like receptors (TLRs) are the membrane proteins that recognize antigens 
such as LPS and fatty acids and oxidized phospholipids, facilitating immune 
responses to infection and stress signals.  To date, 20 TLRs have been identified. 
TLRs signaling consists of 2 pathways dependent on downstream adaptor proteins; 
MyD88-dependent and MyD88-independent pathways (Figure 1.2.4.2.1) (Rauta, 
Samanta, Dash, Nayak, & Das, 2014). MyD88 dependent pathway mainly involves 
in inflammatory cytokine production, while MyD88 independent pathway mediates 
cell proliferation and differentiation.   
 
Figure 1.2.4.2.1 The activation of inflammatory pathway via TLR. A range of 
stimuli such as LPS, FFA and modified lipoprotein activate TLRs and induce 
inflammation via the activity of adaptor protein, MyD88. Activation of TLR by 
stimuli such as interferon  (IFN) also induces the cell response via MyD88 
independent pathway.  (Yamamoto, Takeda, & Akira, 2004) 
 
 
 
TLR2 and TLR4 expression in adipose tissue associated with inflammation 
and insulin resistance. In obesity, TLR4 expression in Om AT is associated with AT 
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expansion (Fusaru et al., 2012). Increased of TLR 2 and TLR4 expression were 
observed in AT taken from obese subjects (S. J. Kim, Choi, Choi, & Park, 2012).  
In addition, high fat diet increased the level of circulating LPS and increased 
of TLR4 expression was observed in C57BL/6 mice, suggesting that dietary fat 
absorption is associated with LPS (N. Wang et al., 2013). In human adipocyte 
primary cell culture, free fatty acid treatment induced TLR4 expression (Creely et al., 
2007; Youssef-Elabd et al., 2012). LPS also induced TLR4 exprssion in adipose 
tissue (Creely et al., 2007; Kopp et al., 2009). Thus, increased lipolysis as well as 
endotoxinaemia in obesity mediates adipose tissue inflammation via TLR pathway.  
 
1.3 Phospholipase enzymes 
Phospholipases are enzymes that have the ability to hydrolyze phospholipids, 
especially glycerophospholipid in plasma membrane. These enzymes are divided 
depending on their type of reaction into two broad groups: (1)   Phospholipases with 
acyl hydrolase activity. These enzymes hydrolyze the phospholipid at the sn-1 acyl 
ester bond (Phospholipase A1) or at the sn-2 acyl ester bond (Phospholipase A2), 
releasing arachidonic acid. (2) Phospholipase with phosphodiesterase activity. These 
enzyme cleaves the glycerol phosphate bond (Phospholipase C) and phospholipase D 
to remove the phosphate group from phospholipid (Capper & Marshall, 2001; 
Pniewska & Pawliczak, 2013; Wilton, 2005) (Figure 1.3.1). 
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Figure 1.3.1 Phospholipases and their sites of action. Phospholipase A 1 (PLA1), 
Phospholipase A2 (PLA2), Phospholipase B (PLB), Phospholipase C (PLC), and 
Phospholipase D (PLD). Adapted from (Mortazavi, Keisary, Loh, Jung, & Khan, 
2011) 
 
They are involved in many cell activities including signal transduction, 
phospholipids membrane synthesis, lipid metabolism and immune activation. As the 
sn-2 position of phospholipids of mammalian cells are enriched with arachidonic 
acid, the substrate of cyclooxygenases, lipoxygenases and P450 monooxygenase, that 
affects PLA2 activity has important implications for inflammation pathway 
(Balsinde, Winstead, & Dennis, 2002; Hui, 2012; Stephen B, 2006). 
1.3.1 Phospholipase A2 
The superfamily of phospholipase A2 (PLA2) is composed of a group of 
enzymes hydrolyzing glycerophospholipids at the sn-2 position. This hydrolysis 
reaction results in the release of free fatty acids such as arachidonic acid and 
lysophospholipids (lysoPL), and both products are important precursors for bioactive 
molecules that play role of various biological functions (Balsinde et al., 2002). 
Based on the activity dependence on calcium ion and sequence homology, the 
mammalian PLA 2 superfamily are categorized into six principal enzymes, sPLA2, 
cPLA2, iPLA2, PAF AH, lysosomal PLA2 and a calcium-dependent intracellular 
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PLA2 being identified in white adipose tissue; denoted as adipose PLA2 (AdPLA2) 
(Capper & Marshall, 2001; Hui, 2012; Sajal, 2003). 
1.3.2 Secreted Phospholipase A2 
The secreted PLA2 (sPLA2) group is the largest and first discovered PLA 2 
type. In mammalian system, 11 sPLA2s types (IB, IIA, IIC, IID, IIE, IIF, II, V, X, 
X12IIA and XIIB) have been identified. They are small protein (14-18 kDa) with 
multidisulfide bonds, containing Ca2+-binding domain. The action of sPLA2 is 
calcium dependent and their target sites are not only in cell membrane but also in 
microvesicles, pulmonary surfactant, lipoprotein, microbial membrane and dietary 
phospholipids (Balestrieri & Arm, 2006; Sajal, 2003; Wilton, 2005). One of the 
primary functions of sPLA2 is the release of arachidonic acid, the precursor of pro-
inflammatory lipid mediators. Therefore, sPLA2s appear to be involved in many 
inflammatory diseases such as rheumatoid arthritis (Jamal et al., 1998), adult 
respiratory distress (Kitsiouli, Nakos, & Lekka, 2009), pancreatitis (S. Xu et al., 
2010) and atherosclerosis (Quach, Arnold, & Cummings, 2014; Rosengren, Jönsson-
Rylander, Peilot, Camejo, & Hurt-Camejo, 2006). 
 sPLA2 type I is considered as a digestive enzyme, mainly express in acinar 
cells of pancreas and  secreted into intestinal lumen (Loweth, Scarpello, & Morgan, 
1995; Peuravuori, Kollanus, & Nevalainen, 2014). The enzyme hydrolyses dietary 
phospholipid into free fatty acid and lysophospholipid which can be absorbed by 
enterocyte and then transport to liver (Lambeau & Gelb, 2008). In knockout mice 
model, the pla2g1b
-/-
 mice were not developed to obesity when induced with the high 
fat/carbohydrate diet (Murakami et al., 2011). 
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 sPLA2 type II is referred as an inflammatory PLA2. It was originally 
extracted from platelet and exudates from patients with rheumatoid arthritis (Jamal et 
al., 1998; Vadas, Stefanski, & Pruzanski, 1985). The Pla2g2a knockout mice also 
had a high risk of joint inflammation when induced with K/BxN autoantibody 
compared to the wild type mice (Eric Boilard, 2010). In additionally, sPLA2 IIA was 
high expression in synovial and chondrocytes in the joint of rheumatoid arthritis 
patients (Jamal et al., 1998) and epicardial adipose tissue of patients who have 
undergone cardiac surgery for coronary artery disease (Anne Dutour, 2010).  
 The role of sPLA2 in atherosclerosis is one of the major topics in this 
research field. Several type of sPLA2 have been reported to associated with LDL and 
HDL hydrolysis, leading to the development of atherosclerosis. For example, 
treatment of LDL with sPLA2 type III (Sato et al., 2008), V (Ohta, Giannattasio, 
Xing, Boyce, & Balestrieri, 2012), X (Kohji Hanasaki, 2002) generated modified 
LDL, enhancing facilitate macrophage form cell formation. Modified HDL by 
sPLA2 reduced cholesterol efflux from lipid loaded macrophages, leading to plague 
formation (Ishimoto, 2003).   
 In contrast to the role of sPLA2 in atherosclerosis and cardiovascular disease, 
their role in metabolic syndrome has not been fully explored. The single nucleotide 
polymorphism analysis showed the association of the human PLA2G5 with serum 
LDL and Oxidized LDL in subjects with type II diabetes (Wootton et al., 2007). In 
animal model, the Pla2g10
-/-
 mice increased obesity (X. Li, Shridas, Forrest, Bailey, 
& Webb, 2010) while the another study failed to find the differences weight between 
the Pla2g10 knockout and wild type mice (Fujioka et al., 2008). 
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1.3.3 Cytosolic Calcium-Dependent Phospholipase A2 
Calcium dependent Phospholipase A2 (cPLA2) family is the intracellular 
enzyme which consists of an N-terminal C2 which binds Ca2+, followed by a 
catalytic domain which has PLA2 and lysophospholipase activity. They have been 
classified into 6 types: cPLA2, cPLA2β, cPLA2γ, cPLA2δ, cPLA2ε and cPLA2ζ 
with a wide range of molecular weight between 61-114 kD. cPLA2 requires Ca2+  
for membrane binding rather than catalysis. In inactivated state, cPLA2 requires 50-
110 mM for being stable at membrane (Clark, Schievella, Nalefski, & Lin, 1995). An 
increase intracellular Ca2+ causes the translocation of the enzyme to membrane and 
subsequently hydrolyzes the membrane phospholipase to release arachidonic acid. It 
is the only PLA2 that shows specificity for phospholipid substrate containing 
arachidonic acid.  
 cPLA2 has a consensus phosphorylation site for MAPK and different 
MAPKs are essential for cPLA2 mediated arachidonic release. cPLA2 can be 
phosphorylated by p42/44 MAPKs (Lin et al., 1993), p38 MAPK, JNK (X. Wang et 
al., 2008). Other kinases such as PKC and cAMP dependent protein kinase A (PKA)  
have been reported as a upper stream cascade of cPLA2 phosphorylation (Olivero & 
Ganey, 2000).  
As arachidonic acid is an initial precursor of the inflammatory mediator, the 
association of cPLA2 expression with activity in various inflammatory diseases has 
been documented. Studies of cPLA2 knockout mice have a normal appearance with 
approximately 1.5 year longer life span (Bonventre & Sapirstein, 1999). However, 
then cPLA2 
-/- 
mice showed a defect in reproduction. Pregnancy in the cPLA2 
-/- 
mice 
was terminated after implantation due to the increase of vascular permeability in 
endometrium during implantation (Sapirstein & Bonventre, 2000). Under 
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pathophysiological state, the cPLA2 knockout mice showed different responses 
compared to wild type. In the LPS and zymosan induced adult respiratory distress 
syndrome, pulmonary edema, macrophage infiltration and deterioration of gas 
exchange are markedly reduced in cPLA2 knockout mice (Sapirstein & Bonventre, 
2000). In 1-methyl-4-phenyl-1,2,3,6 –tetrahydropyridine induced brain injury model, 
cPLA2 knockout mice showed less reduction of brain striatail dopamine, the brain 
injury marker (Bonventre, 1998). These studies taken together suggest an important 
role of cPLA2 in various diseases.   
1.3.4 Cytosolic Calcium-Independent Phospholipase A2 
The calcium independent phospholipase A2 (iPLA2) family consists of a 
lipid hydrolase domain which was initially discovered in a potato tuber, patatin. They 
are also called patatin like phospholipase domain containing lipases (PNPLAs). Nine 
types of the human PNPLAs have been identified in human. The group of enzymes 
bearing an N-terminal region act mainly on phospholipase are called as 
phospholipase type which consists 4 enzymes member, iPLA2β, iPLA2γ, iPLA2δ 
and NRE, whereas the group of enzymes that lack of the N-terminal domain, mainly 
act of lipids, are so called Lipase type. There are 5 enzymes have been classified into 
the lipase type, iPLA2ε, iPLA2ζ, iPLA2η, PNPLA1 and PNPLA2. It is fully active in 
the absence of Ca2+ and the activity is not specific to the 2sn-fatty acid (Kudo & 
Murakami, 2002; Sajal, 2003; Schaloske & Dennis, 2006). 
 The classical iPLA2β plays a role in membrane remodeling to maintain the 
cell homoeostasis (Balgoma, Montero, Balboa, & Balsinde, 2010). Inhibition on 
iPLA2β via BEL treatment or antisense oligonucleotide lead to reduced AA 
incorporation into PLs and cellular LPC levels in P388D1 macrophages (Dennis, 
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1997). Similar results are also found in brain cell studies: it has been reported that 
BEL treatment inhibits the release of docosahexaenoic acid from the membrane 
phospholipids of astrocytes upon ATP stimulation (Green, Orr, & Bazinet, 2008). In 
contrast, overexpression of iPLA2 β and iPLA2γ in HEK293 cells results in the 
accumulation of free fatty acid and LPC, and this event can be blunted by BEL 
(Makoto Murakami, 2005). However, in Pla2g6 
-/- 
mice did not show the different in 
phospholipid composition in testis, pancreatic β cell and peritoneal macrophage 
(Yoda et al., 2010), indicating that iPLA2 activity could be compensated by other 
phospholipase enzyme. 
 Recently, several studies established the roles of iPLA2 β in glucose-
stimulated insulin secretion and glucose homeostasis. The Pla2g6 
-/-
 mice showed no 
different blood glucose after feeding the chow diet, compared to wild type, but the 
knockout mice developed more severe hyperglycemia after admistration of 
streptozotocin, the β cell toxin (Bao et al., 2006; Song et al., 2010). In the 
overexpression mouse model, lower blood glucose and higher insulin in circulation 
at fasting were observed (Bao et al., 2008). These findings indicated that iPLA2 
might be involved in insulin secretion. iPLA2β could be unregulated under high 
glucose condition. A high glucose treatment in vascular smooth muscle cell induced 
iPLA2 β expression via PKC activation, corresponding with the high expression of 
this gene in vascular tissue taken from patient with type II diabetes (Z. Xie et al., 
2010). 
Moreover, reactive oxygen species (ROS), including superoxide anion, 
hydroxyl radical and hydrogen peroxide have been known to potentiate iPLA2 
activity (Sun et al., 2001; J. F. Xu, Yu, Sun, & Sun, 2003). When the uterine stromal 
cells were stimulated by hydrogen peroxide, a significant increase in iPLA2 was 
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detected via the increased calcium-independent arachidonic release (Birbes, Gothié, 
Pageaux, Lagarde, & Laugier, 2000). Similarly, in RAW 264.7 cells or mouse 
peritoneal macrophages, both hydrogen peroxide and superoxide anion treatments 
led to increases in iPLA2 activity (Martinez & Moreno, 2001). 
1.3.5 Platelet-Activating Factor Acetylhydrolase 
Platelet-activating factor acetylhydrolases (PAF-AHs) catalyze the 
acylhydrolysis at the sn-2 position of PAF to liberate acetate and lysoPAF. It also 
hydrolyzes the phospholipids with the oxidized fatty acid acyl group from the sn-2 
position of PC and PE. In addition to the acylhydrolase activity, this enzyme also 
exhibits the transacetylase activity which transfers acetate or short chain fatty acid to 
lysoPAF and other lysophospholipases. Thereby, the two activities of this enzyme 
might help cells to control the level of PAF. These enzyme groups compose of four 
serine enzymes assigned to two numbering groups, group VII and group VIII PLA2 
(Hui, 2012; Sajal, 2003; Wilton, 2005). The plasma type PAF AH or lipoprotein-
associated PLA 2 is the only secretory protein while the other three are all cytosolic 
proteins. The major source of LpPLA2 in plasma is likely contributed by monocyte 
derived macrophage, T lymphocyte and mast cell (A. Cai, Zheng, Qiu, Mai, & Zhou, 
2013; Rosenson & Hurt-Camejo, 2012). Recently, it LpPLA2 has been proposed as a 
new biomarker used for monitoring metabolic syndrome and CVD (Toth, 
McCullough, Wegner, & Colley, 2010). 
1.3.6 Lysosomal PLA2 
Lysosomal phosphoslipase A2 consists of two distinct enzymes, acidic Ca2
+
 
independent PLA2 (aiPLA2) or peroxiredoxin 6 and a macrophage lysosomal PLA2 
(LPLA2) or group XV PLA2 (Sajal, 2003). The aiPLA2 is an anti-oxidant enzyme, 
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possessing glutathione peroxidease and phospholipase activity. The aiPLA2 
knockout mice showed more sensitivity to oxidant agent (L. Li et al., 2007). It also 
involves in lung surfactant synthesis. The aiPLA2 knochout mice increased 
degradation of dipamitoyl-PC, lung surfactant, indicating its role in respiratory 
diseases (A. B. Fisher, Dodia, Yu, Manevich, & Feinstein, 2006; Manevich & Fisher, 
2005). LPLA2 hydrolyzes PC and PE in Ca2+ independent manner. It is fully active 
in pH4.5 and preferentially localized in macrophage alveolar (Abe et al., 2004). The 
knockout of LPLA2 gene in mice showed foam cell formation in macrophage and 
increased the surfactant lipid accumulation (Hiraoka et al., 2006).  
1.3.7 Adipose specific PLA2 
Identification of adPLA2 or PLA2 group XVI first reported in 2008. It 
appears abundantly expressed in white adipose tissue and generates free fatty acid 
and lysophospholipid from phosphatidylcholine with a preference at the 2sn-position 
(Duncan, Sarkadi-Nagy, Jaworski, Ahmadian, & Sul, 2008). Pla2g16
-/- 
mice are lean 
and have a reduced WAT mass with a low triglyceride and PEG2 content (Jaworski 
et al., 2009), indicated that AdPLA2 is crucial in the development of obesity.  
1.4 Arachidonic acid pathway  
Activation of PhospholipaseA2 provides the arachidonic acid release. The 
free arachidonic acid may subsequently metabolized by one of the three pathways; 
cyclooxygenase pathway, Lipoxygenase pathway and P450 monooxygenase, 
producing ecosanoids (Hyde & Missailidis, 2009). Due to the potent biological 
function of ecosanoids, cells keep the free arachidonic acid at a very low level by 
regulating phospholipaseA2 activity (Astudillo, Balgoma, Balboa, & Balsinde, 2012)  
  
29 
 
and arachidonic acid itself can induces cell apoptosis(Pompeia, Freitas, Kim, 
Zyngier, & Curi, 2002).   
1.4.1 The role of Phospholipase A2 in arahidonic acid release. 
Arachidonic acid is a polyunsaturated 6 fatty acid, 20:4(6), esterified into 
the 2sn-position of glycerolphospholipids located in the cell membrane. Body 
directly obtains this fatty acid from diet or alternately synthesizes from linoleic acid. 
The arachidonic acid release is restrictively control because it is a common precursor 
of eicosanoids which are the mediators of inflammatory reaction. Cells regulate the 
level of free arachidonic acid by two pathways depending on the intracellular level of 
the free fatty acid. Under physiological condition, the low concentration of 
arachidonic acid incorporates into lysophospholipids to form the 
glycerolphospholipids. This process generally takes several hours in primary cells 
and is considered to be the major pathway to control the arachidonic acid release 
(Pérez-Chacón, Astudillo, Balgoma, Balboa, & Balsinde, 2009). As lysophospholipid 
is necessary as an acceptor of free arachidonic acid in this process, the PLA2 activity 
may play a key role in arachidonic acid releases because it provides the availability 
of lysophopholipids. Under the pathological condition, the high arachidonic acid 
incorporates into triacylglycerol and dirachidonoyl phospholipids via the de novo 
pathway (Balsinde et al., 2002; Chilton, Fonteh, Surette, Triggiani, & Winkler, 
1996). 
1.4.2 Cyclooxygenase pathway 
Cyclooxygenase (COX; Prostaglandin G/H synthase) exist of two isoforms, 
COX1 and COX2. COX1 is a housekeeping enzyme responsible to sustain the 
prostanoids level in order to maintain the cell homeostasis. COX2 is undetectable 
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under normal physiological condition but it can be induced in response to hypoxia, 
inflammation and cytokines (Cole, Kuhn, et al., 2012; Rizzo, 2011). These enzymes 
catalyze the stepwise conversion of arachidonic acid into the reactive intermediates 
PGG and PGH, which are the precursor of prostaglandins and thomboxanes 
(Simmons, Botting, & Hla, 2004; Vegiopoulos et al., 2010) (Figure 1.4.2.1). COX2 
has been reported to be expressed in adipose tissue (Cao et al., 2011; Chu et al., 
2010; Vegiopoulos et al., 2010) and the mRNA of COX2 and TNF are noted to be 
increased in high fat diet induced obese rats (Cao et al., 2011; Chu et al., 2010). 
Stable transfection of antisense COX2 increased 3T3-L1 adipocyte differentiation, 
accompanying a decrease in PGE 2 and PGF 2 levels(Chu et al., 2010). 
 
Figure 1.4.2.1 Cyclooxygenase pathway (Garzón, Oeste, Díez-Dacal, & Pérez-Sala, 
2011) 
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1.4.3 Lipooxygenase pathway 
 In mammals, LOXs were categorized with respect to their positional 
specificity of arachidonic acid oxygenation into 4 major types, 5-LOXs, 8LOXs, 
12LOXs and 15LOXs (Kühn & O’Donnell, 2006). Lipoxygenases oxygenate 
arachidonic acid in different position along the carbon chain, producing the 
corresponding 5S-, 12S- of 15S- hydroperoxides (hydroperoxyeicosatetraenoic acid, 
HPETEs) (Funk, Chen, Johnson, & Zhao, 2002). The hydroperoxides can further 
convert this into leukotrienes, hepoxylins and lipoxins which are important as 
mediators of inflammation in various cells (Borgeat & Naccache, 1990) (Figure 
1.4.3.1). 
 
 
 
Figure 1.4.3.1. Lipoxygenases pathway (Dobrian et al., 2011) 
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 The most interesting product in this pathway is LTB4. LTB4 is a ligand for 
peroxisome proliferator receptor alpha (PPAR) which involves in lipid metabolism 
as well as mitochondria β oxidation (Latruffe & Vamecq, 1997). In addition, LTB 
induced monocyte chemoattractant protein 1 (MCP1) in human monocyte, mediating 
allergic inflammation and asthma allergic inflammation and asthma (Ogawa & 
Calhoun, 2006). 
1.4.4 P450 monooxygenase 
 Cytochrome P450 (CYP450) monooxygenases are the enzyme family that 
synthesizes epoxyeicosatrienoic acid (EETs) and hydroxyeicosatetraenoic acid 
(HETEs) from arachidonic acid. (X. Xu, Zhang, & Wang, 2011).  Recently, the CYP 
pathway has wildly studied regarding its role in regulation of vascular tone (Rahman, 
Wright Jr, & Douglas, 1997; Sacerdoti et al., 2011). EETs are associated with 
vasorelaxation and ion transportation in kidney, leading to regulation of renal blood 
flow and Na+ reabsorption, resulting in blood pressure reduction (Rahman et al., 
1997) 
 Several studies indicated EETs are involved as a key inflammatory mediator. 
Direct administration of 11,12EET attenuated TNF induced NB activation in 
HUVECs (Fleming et al., 2001). Similarly, incubation the cells with EETs and their 
specific inhibitor prevented IB degradation, inhibiting NFB activation (Y. Liu et 
al., 2005). Moreover, the anti-atherosclerotic effect has been reported. The inhibitor 
of sEH reduced the atherosclerotic lesion and the reduction of serum lipid, IL6, IL8, 
IL1 were also observed in a model of abdominal aortic aneurysm apolipoparotein E 
deficiency mice (Zhang et al., 2009).  
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1.5 LpPLA2 as a marker for monitoring cardiovascular diseases 
Prevalence of cardiovascular diseases is strongly associated with obesity 
T2DM. The link between obesity and pathogenesis of cardiovascular diseases is 
complicate and involved by organs that play critical roles in energy metabolism. It is 
fundamentally associated with increased lipids in circulation, endothelial 
inflammation and accumulation of modified lipids within vascular wall (Douglas & 
Channon, 2010).  Currently, subclinical atherosclerosis, namely as metabolic 
syndromes, is diagnosed in order to predict and prevent at high risk for CVD and 
T2DM in clinical practice. Currently, the National Cholesterol Education Program-
Adult Treatment Panel III (NCEP-ATP III) has proposed a new criteria for screening 
CVD risks with the presence of at least three of five criteria; (1) 
hypertriglyceridnemia, (2) low HDL, (3) abnormal fasting blood glucose, (4)   
increased waist circumference, and (5) hypertension, is diagnosed as metabolic 
syndromes (MS) (Expert Panel on Detection, 2001).  
1.5.1 Pathology of atherosclerosis 
 Increased production of circulating lipoprotein in liver together with 
reduction of fat storage capacity in AT are the factors that contribute to increased 
circulating LDL, TG and free fatty acid. Prolong LDL in circulation is susceptible to 
modification, especially by oxidation. Under the hypertension condition, ox-LDLs 
are penetrated into endothelial intima and subsequently induce macrophage 
infiltration into the plaque. Excessive macrophage uptakes of modified lipids create 
foam cells and deposit inside the vascular wall. Activated macrophages secret 
inflammatory cytokines and induce endothelial cell inflammation, which 
consequently increases the generation of reactive oxygen species (ROS). Cytokines 
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such as TNF induced apoptosis of the foam cells, leading to accumulation of death 
cells which aggravate tissue damage (Douglas & Channon, 2010) (Figure 1.5.1.1).  
 
Figure 1.5.1.1 Pathogenesis of atherosclerosis (Douglas & Channon, 2010) 
 
1.5.2 LpPLA2 and atherosclerosis 
The majority of plasma LpPLA2 in healthy subjects bound to LDL and small 
proportion is associated with HDL. Plasma LpPLA2 is closely correlated with LDL 
and increased in obesity and T2DM. Currently, it has been proposed as a biomarker 
for cardiovascular diseases (A. Cai et al., 2013; Dallmeier & Koenig, 2014). 
Increased circulating LpPLA2 is associated with metabolic diseases such as T2DM 
  
35 
 
(Fortunato et al., 2014) and CVD (J. Liu et al., 2014). Study in patients undergoing 
carotid endarterectomy showed the high expression of LpPLA2 and 
lysophosphatidylcholine in plaques.  
However, the role of LpPLA2 in atherosclerosis is controversial since its 
biological function mediates both anti atherogenic and pro atherogenic effects. The 
anti atherogenic primitively ascribed to its ability to degrade platelet activating factor 
(PAF) and hydrolyze ox-LDL, minimizing macrophage recognition. This process 
subsequently liberates lysophosphatidylcholine (LysoPC) and oxidized free fatty 
acids (ox-NEFA) which can induce apoptosis and further oxidize intact LDL. 
oxNEFA and LysoPC also induce various of inflammatory cytokine, worsen 
inflammation in the pathogenic lesion, exhibiting its pro-atherogenic effect (Figure 
1.5.2.1).  
 
Figure 1.5.2.1 Hydrolysis of ox-LDL by LpPLA2. (Macphee, Nelson, & Zalewski, 
2006)  
 
  However, the massive over-expression of LpPLA2 gene in apoliprotein E 
(apoE) 
-/-
 mice, which increased approximately 76-140 fold of plasma LpPLA2, 
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showed the protective effect of lipoprotein oxidation induced by copper ion. Whilst, 
diabetic/hypercholesterolemia animal model treated with LpPLA2 inhibitor markedly 
reduced the lysophosphatidylcholine in lesions and mitigated the development of 
atherosclerosis (Schmitz & Ruebsaamen, 2010). The controversial evidence 
demonstrated that LpPLA2 might be involved in complementary or opposite 
pathways in atherosclerosis, the understanding of expression, function and regulation 
of LpPLA2 in specific tissue and diseases state in different species might help to 
understand the CVD pathology. 
 
1.6 Thesis Aim 
 Adiposity is a pathological condition leads to comordiality complications, 
including T2DM and cardiovascular diseases. Dysregulation of lipolysis and 
lipogenesis in AT expansion is a contributor of increased non-esterified fatty acid 
and circulating lipoproteins, especially LDL and oxLDL. Recently, LpPLA2 has 
been proposed as a new marker for CVD risk since extensive evident supported the 
strong association between prevalence of metabolic diseases and LpPLA2. It has 
been reported to express in immune cells and secreted to into circulation. In 
circulation, this enzyme mostly bound to LDL particles. LpPLA2 possesses both 
anti- and pro-atherogenic properties due to its biological activity. In LpPLA2 
overexpression model, LpPLA2 exhibited the protective effects against lipoprotein 
oxidation, whilst in LpPLA2 inhibitor study, inhibition of LpPLA2 reduced the CVD 
progression. Thus, the understanding of expression, function and regulation of 
LpPLA2 in specific tissue and diseases state in different species might help to 
understand the link between adiposity and CVD pathology. 
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To date, there is no evident of role of LpPLA2 in AT. This thesis sought to 
(1) characterise PLA2 isoforms in lean, obese, T2DM abdominal subcutaneous 
(AbdSc) and omental (Om) in human adipose tissue (AT); (2) evaluate the role of 
lipids and inflammatory markers on circulating LpPLA2, and (3) determine the in 
vitro regulation of LpPLA2 in human adipocytes by its influence on LDL and Ox-
LDL.  
The mechanism underlying AT inflammation is mainly involved with NFB 
pathway. Activation of TLRs potentiates NFB activity. Previously, NEFA and ox-
LDL have been reported to increase the TLR4 expression. Therefore, this study sort 
to investigate the impact of lipid changes in bariatric patients on TLRs expression as 
well as its adaptor protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 2 : General Methods and Materials 
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2. General Methods and Materials 
ALL materials and methods used throughout this thesis were described in this 
chapter. The detail of reagent preparations and experiment protocols were in 
appendix A.  
2.1 Adipose tissue collection  
Paired human Sc and Om AT biopsies were taken from patients undergoing 
elective surgery. Subjects with a history of cancers as well as endocrine diseases or 
on treatment were excluded. None of the subjects was taking anti-inflammatory 
drugs or steroid drugs. Detailed medical drug histories were also taken. Ethical 
approval was obtained from the local ethics committee and all subjects gave written 
consent prior to enrolment. AT samples were frozen or processed for future use 
immediately after collection in order to inhibit the alteration of AT metabolism and 
cell lysis. 
2.1.1 Adipose tissue freezing 
AT sample were cut and aliquoted into a sterile centrifuge tube and 
immediately frozen in liquid nitrogen (N2). After AT samples were completely 
frozen, the tubes were directly transferred into -80
0
C freezer.  The frozen samples 
can also be kept in N2 for longer storages.  
2.1.2 Mature and pre-adipocyte isolation from AT 
AT composed not only of pre-adipocyte but also the connective tissue and 
immunological cells. To isolation pre-adipocyte, approximately 10-20 ml of AT was 
finely cut and transferred into 50 ml sterile centrifuge tube containing 10 ml of warm 
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collagenase (2mg/mL in HBSS, Worthington Biochemical Corporation, New Jersay, 
USA), then mixed vigorously under biological cabinet II. Subsequently, the 
AT/collagenase mixture was incubated in 37
0
C shaking water bath for 30 minutes 
(min) with shaking at 10 mins interval to distribute collagenase evenly and digest the 
connective tissue.  
After 30 min incubation, the centrifuge tubes were moved to a biological 
cabinet II and the mixture was filtered through a layer sterile cotton mesh into a new 
50 mL sterile centrifuge tube, then centrifuge at 300-350 g for 5 mins. The mixture 
was then separated into three layers according to difference of density after 
centrifugation. The lowest density layer which consisted of mature adipocyte filled 
with lipid was on the top. The highest density, the stroma-vascular fraction 
containing several types of cells, together with pre-adipocyte, macrophage and 
leukocyte, was on the bottom. The middle layer was aqueous solution contain 
collagenase.  
To collect the mature adipocytes, approximately 5 mL of the top creamy layer 
was gently transferred to a new sterile centrifuge tube. The cells were then carefully 
suspended with 10 mL of warmed serum free Dulbecco’s modified Eagle’s medium 
with high glucose (DMEM/F12) by manually inverting the tube. The tubes were then 
centrifuged at 300-350 g for 5 mins to remove contamination of collagenase and 
blood. The mature adipocytes were on the top layer and the aqueous layer underneath 
was carefully removed by using a sterile seropipette. This step was repeated until the 
adipocyte layer was appeared to free from blood. To keep the mature adipocytes for 
future works, the adipocyte layer was then aliquoted approximately 1 mL into sterile 
cryotube and quickly placed into dry ice to freeze the cells. The frozen cells were 
then kept in -80
0
C until use.  
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To culture the cells, the pellet was carefully mixed and counted cell numbers 
by using heamatocytometer. Five thousand cells (100,000 cells/mL) were transferred 
into 25cm
2
 culture flask containing completed media 10% fetal bovine (FBS), 
20U/ml penicillin/Streptomycin and 10 µg/mL transferin in DMEM/F12 (phenol red 
free) and incubated at 37
0
C, 5%CO2 incubator for at least 16 hr to let the cells 
attached to the flask surface. After 16 hr, the media was removed to get rid of death 
cells and changed into fresh completed media. 
2.1.3 Purity of adipocyte fraction isolated from AT 
The contamination of monocyte/macrophage was observed by using 
immunohistochemistry with antibody against macrophage specific markers as 
described in the relevant chapters.       
2.3 Human adipocyte culture 
2.3.1 Human pre-adipocyte cell line 
Chub-S7 was used as an in vitro experiment model throughout this thesis. It 
was firstly established in 2003. This cell line derived from subcutaneous abdominal 
white adipocyte taken from 33 years old women with BMI 52 Kg/m
2
. The pre-
adipocyte precursors were transfected with human telomerase reverse transcriptase 
and papillomavirus E7 oncoprotein in order to immortalize and conserve human pre 
adipocyte properties (Darimont, 2003). Similar to primary cell culture, Chub-S7 cells 
were maintained in Dulbecco’s modified Eagle’s medium with high glucose 
(DMEM/F12) supplement with 10% FBS, 20U/ml penicillin/Streptomycin and 
10µg/mL transferrin in 37
0
C and 5% CO2 incubator. 
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2.3.2 Human pre adipocyte differentiation 
The cells were grown until confluence. Then, cells were replaced the growth 
media with Differentiation media DMEM/F12 supplement with pre-adipocyte 
differentiation media supplement (Promocell) to promote cell differentiation. The 
media was changed every 48 hr for 4 days. At Day4, replace the Differentiation 
media with Nutrition media which contained DMEM/F12 supplement with adipocyte 
nutrition media supplement (Promocell) and fed the cells with fresh Nutrition media 
every 2-3 days for at least 14 days to increase adipogenesis during differentiation 
process. The cells were used for the relevant experiments at day 14.  
 
2.4 Cell viability examination by Trypan Blue dye exclusion test 
 Cell viability was observed by visual method using light microscope. This 
method was based on cell membrane permeability of the living cells. Ten microlitters 
of adipocytes were re-suspended in 10µL of 0.4% trypan blue (Sigma, UK) in 
phosphate buffer saline (PBS, pH 7.6) for 5 min in room temperature (RT). The 
living cells are able to efflux the dye out of the cells, whist the death cells uptake the 
dye. Cell viability and numbers were counted using haemocytometer. The death cells 
stain blue. 
2.5 Protein isolation 
2.5.1 Protein isolation from AT 
Approximately 50 mg of Human AT was quickly cut into tiny pieces, then 
transfers into sterile 15 mL tube. The sample was re-suspended in 1 mL of cold 
Phosphosafe™ Extraction buffer (Novogen ®, Merck, Germany) and homogenized 
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at 1,000 g for 30 secs by a Rotor-Stator Homogenizer (PowerGen125, Fisher 
Scientific, UK). The cell lysate was then transferred to 1.5 mL microcentrifuge tube 
and rapidly placed in liquid N2 to freeze the cell lysate. Subsequently, samples were 
then removed and allowed to thaw at RT. After thawing, the microcentrifuge tubes 
were then spun at 18,000 g at 4
0
C for 30 min. The samples were then separated into 
three layers after centrifugation. The cellular protein fraction was in the middle 
between the lipid layer and cell debris. The protein layer was carefully collected by 
using syringes and hypodermic needles, transferred to a sterile 1.5 mL 
microcentrifuge tube and kept in -80
0
C freezer until use.   
2.5.2 Cell trypsinization 
The adherent adipocytes were detached from culture flask or plate by 
treatment of trypsin-EDTA solution (Gibco, UK). For this procedure, culture media 
was removed and the cells were washed three times with cold PBS. Then, the cells 
were incubated with 2.5 mL of 37
0
C warmed 0.25% trypsin-EDTA solution for 3-5 
mins (maximum 5 mins) at 37
0
C. The trypsin-EDTA solution was then removed and 
quickly added 5 mL of completed media to stop trypsin activity. The mixture was 
gently re-suspened by using sterile seropipette and checked the detachment under 
light microscope. All cells should be separated nicely without any clump. The cell 
mixture was then transferred to 50 mL centrifuge tube and centrifuged at 2500 rpm 
for 10 min. The supernatant was then discarded. Cell pellet was washed for three 
times. 
2.5.3 Protein isolation from cell culture. 
After trypsinization, the cell pellets were lysed by adding 500 µL of cold 
Radio-Immunoprecipitation Assay (RIPA) buffer (Thermo Scientific, UK) 
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containing protease inhibitors cocktail and phosphatase inhibitors reagent. For the 
cells in 6 wells plate, 200 µL of RIPA were used. The samples were then incubated 
for 10 mins on ice with gentry shaking. After that, the samples were well mixed and 
collected by using pipette or cell scraper. The samples were centrifuged at 18,000 g 
for 10 mins, 4
0
C. The supernatants were collected in 1.5 mL microcentrifuge tubes, 
rapidly frozen in liquid N2 and kept in -80
0
C until use.       
2.6 Quantification of cellular protein concentration 
2.6.1 Lowry method 
Protein concentrations
 
in samples that contained RIPA buffer were 
determined by using the Bio-Rad DC
TM
 protein
 
assay kit (Bio-Rad Laboratories, 
Hercules, CA). This method is based on the reduction of mixed acids in Folin reagent 
(phosphomolybdic-tungstic acids) by protein, producing blue colour of reduced 
forms of the acids. For this procedure, the protein samples in RIPA buffer were 
vortexed after allowed to thaw at RT. Working reagent was prepared by mixing 980 
µL of reagent A (alkaline copper tartate solution) with 20µL of Reagent S 
(Surfactant) in glass test tubes. Five microliters of protein sample was added test 
tubes. One hundred and twenty microliters of working reagent was then added to the 
test tube, followed by 1 mL of reagent B (diluted folin reagent) and mixed by 
inversion. The mixture was then incubated for 15 mins at RT. The absorbance of the 
product was then quantified by spectrophotometer at a wavelength of 655nm.  
2.6.2 Bradford assay 
To quantify protein concentration in samples resuspended in non-detergent 
buffer, the BioRad Bradford protein assay kit was used (Bio-Rad Laboratories, 
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Hercules, CA). Bradford assay is based on the alteration of red cationic form of 
Coomassie brilliant blue G-250 to blue anionic form, induced by protein binding. In 
short, concentrate Bradford reagent was diluted 1:5 with distilled water 
(approximately absorbance was 0.500 at 595 nm). One microliter of protein sample 
was mixed with 1 mL of working Bradford reagent and incubated for 5 mins at RT. 
The absorbance was measured at 595 nm.   
2.7 Determination of protein expression by western blot 
Western blot is an analytical technique used in identification and 
quantification of the certain protein in a protein mixture. In western blot, mixture of 
proteins was run through sodium dodecyl sulphate polyacrylamide gel which allowed 
proteins in the sample separated by size. Separated proteins in the gel were then 
transferred into PVDF
TM
 membrane by applying an electric current. The membrane 
was then immersed in blocking reagent in order to cover the area that not blotted on 
the membrane in order to prevent non specific binding of antibody. The protein of 
interest was probed by specific antibody at an appropriate dilution as described in the 
relevant chapters. The specific protein band was then quantified by using ECL.   
2.7.1 Sample preparation 
Protein samples were diluted into 20 or 40 µg/20µL (20 µL of 1 or 2 µg/µL, 
respectively) with deionized water and added 5µL of 5X loading buffer containing 
SDS, -mercaptoethanol, glycerol and bromphenol blue (Geneflow, UK). The 
samples were boiled at 95
0
C for 5 mins. In this step, proteins in the sample were 
denatured by heating and -mercaptoethanol which was used to reduce the protein 
disulfide bond. The denatured peptides attached with SDS in a constant mass ratio 
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(1.4:1), creating rod shape with negative of polypeptides. Glycerol was added to 
prevent sample overflow and uneven sample loading. Anionic bromphenol blue dye 
was used for monitoring the protein migration progress. After 5 mins, the samples 
were the placed on ice for 2-5 mins.  
2.7.2 Electropheresis 
Each protein in the sample mixture was separated according to its molecular 
weight and the porous acrylamide gel. Percentage of acrylamide affected the porous 
sizes with higher percentage created smaller pore. Thus, 7% and 10% acraylamide 
were used for protein with MW < 50 and > 50 kilodalton (kDa), respectively.  
For gel preparation, 1.5 mm glass plates were wiped with absolute methanol and 
allowed to dry. The clean glass plates and a rack of solidification were assembled 
according to manufacturer’s instruction. Distilled water was poured between the 
glass plates to test leakiness. Fifty milliliter of 7.5 or 10% separating gel solution was 
prepared just before gel pouring. Once TEMED was added to the separating gel 
solution, the solution mixture was quickly and gentry mix and immediately poured 
into the gel casings until the level is equally at the top of the green grips of the rack. 
Distilled water or absolute of methanol was overlaid on the top of the separating gel 
solution and left approximately 30-45 mins at RT to complete gel polymerization. 
The 4% stacking gel was then prepared. Once the gels were set, the stacking gel 
solution was added by using pipette, after removing distilled water or methanol. The 
1.5 mm thick, 10 wells comb was immediately inserted into the stacking gel to create 
wells, avoiding creating bubbles. Completely polymerization of the gel took 
approximately 1 hr at RT. After the gels were set, the comb was carefully removed 
and the wells were washed by distilled water to remove the excess un-polymerized 
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acrylamide. The glass plates with polymerized gels were then placed inside an 
electrophorator tank and filled the tank with 1L of running buffer, ensuring the gels 
were completely covered with the buffer. The sample tubes were briefly centrifuged 
and 25 µL of samples were loaded to each wells, followed by 5 µL of molecular 
weight protein markers well. An electrophorator was then connected with power 
supply using a fixed voltage of 100V. The electrophoresis was run approximately 1 
hr and 1.30 hr for 7% and 10% separating gel respectively or until the dye fronts ran 
to the bottom of the gels.          
2.7.3 Electroblotting 
Electroblotting is the technique that transfers protein onto a membrane. 
Following electrophoresis, the glass plates with the gels were removed from the tank 
and carefully released the gel from the glass plate. The stacking gel layer was cut and 
discarded, and then the gel was washed in cold transfer buffer. To prepare a standard 
transfer stack, 2 sheets of filter papers and 2 fibre pads were soaked in cold transfer 
buffer at least 10 mins. Immobilon-P
TM
 PVDF membrane (0.45µm; Millipore, USA) 
was immersed in absolute methanol and subsequently soaked in cold transfer buffer 
at least for 10 mins. To set up a transfer stack from anode to cathode, a fiber pad was 
firstly laid over the black side of the transfer cassette, followed by a filter paper, gel, 
PVDF membrane, filter paper and a fiber pad. The stack then was placed in the 
electrotransfer unit, containing cold transfer buffer and ice pack. The cassette needed 
to be covered with the buffer and a magnetic stirrer was also put in the tank. The 
electrotransfer unit was then placed onto a magnetic stirrer in order to reduce the heat 
that produced by electric current. The peptides on the gels were transferred at 100 V, 
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1 hr for 1.5 mm thick gel. Overnight transfer with a constant voltage of 25 would be 
done for high molecular weight protein.                
2.7.4 Antibody detection 
After electroblotting, the membrane was removed from the cassette and then 
quick wash with PBS. The membrane was submerged in blocking reagent to reduce 
non-specific binding background on an orbital shaker for at least 4 hr at RT, or 
overnight at 4
0
C. After incubation, the membrane was then quickly washed with 
PBS-Tween 20 (0.1% PBS-T) and incubated with primary antibody which was 
diluted with 5 mL of 0.2% I-block in PBS-T at a specific dilution, described in the 
relevant chapters. The incubation time varies depend on primary antibody with the 
short time incubation (1-2 hr) was done at RT, while the longer incubation 
(overnight) was done at 4
0
C.The membrane was then washed to get rid of excess 
primary antibody for 5 times, 5 mins each, with PBS-T on orbital shaking and 
avoided to leave the membrane of 0.1% PBS-T for too long.  
The binding of primary antibody with peptides on the membrane was 
detected by using secondary antibody conjugated with enzyme such as horseradish 
peroxidase. The secondary antibody was also diluted with 5 mL of 0.2% I-block in 
PBS-T. The membrane was incubated for 1 hr and then washed with PBS-T for 5 
times, 5 mins each.   
2.7.5 Quantification of protein bands 
The horseradish peroxidase conjugated secondary antibody was detected by 
using a chemiluminescent detection
 
system, ECL/ECL
+
 (Amersham Pharmacia 
Biotech, Little Chalfont,
 
UK). In chemiluminescent reaction, luminol was used as a 
substrate for peroxidase, creating emission of light at 428 nm.  The light intensity 
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was increased up to 1,000 fold by p-iodophenol. The light emission was visualized 
using Hyperfilm 
TM 
(Amersham Pharmacia Biotech, Little Chalfont,
 
UK) within 60 
mins. For procedure, after secondary antibody incubations, the membrane was rinsed 
with PBS-T for 5 times, 5 mins each. Equal volume of reagent A and B were mixed 
just before use. The membrane was placed over the clear thin film in the orientation 
that allowed the peptide blotted site to expose the chemiluminescent reagent. 
Sufficient volume of the chemiluminescent reagent was poured to the membrane and 
incubated fir 1 min in dark. Then, the membrane was wrapped with the clear thin 
plastic wallet. The membrane in the wallet was placed inside the X-ray film cassette. 
To develop the film, a hyperfilm 
TM
 was placed over the membrane inside the 
cassette. This process needed to be done in the dark room. The exposure time of the 
film and the membrane depended on the light signal, which normally took 10-60 
mins. The band density was then quantified by (Genesnap, Syngene, UK). 
2.8 RNA isolation  
 To isolate total RNA from AT, approximately 50 mg of AT was cut and 
resuspended in 1 mL of QIAzol lysis reagent (QIAGEN, UK). The samples were 
then homogenized using a Rotor-Stator Homogenizer (PowerGen125, Fisher 
Scientific, UK) at 1000g for 1sec. For cell culture, adipocytes were rinsed with cold 
PBS and 250 µL of QIAzol lysis reagent was added directly to the culture plates. The 
plates were then incubated for 10 mins on ice tray with gentry shaking, and scraping 
the adipocytes with cell scraper.  
Samples in QIAzol were extracted for total RNA by using a column based 
method (RNeasy lipid tissue kit, Qiagen, UK), according to the manufacturer’s 
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instructions. Extraction was followed by a DNase digestion step (DNase I kit, Sigma, 
UK) to remove any contaminating genomic DNA.  
2.8.1 RNA Quantification 
 Total RNA concentration was quantified by Nanodrop ND-1000 
Spectrophotometer (LabTech, UK). The absorbance was measured at 260 (mainly 
absorbed by RNA) and 280 (absorbed by protein, solvents, salts) nm. The absorbance 
260/280 ratio was assessed to estimate RNA purity with the ratio of 1.8-2.0 was 
acceptable for the next steps. Contamination by phenols was also estimated by 
measuring the absorbance at 230 and the 260/230 ratio of 1.8-2.0 was represented a 
highly purified RNA.  
2.8.2 cDNA synthesis 
Two hundreds nanogrames of RNA from each sample was reverse 
transcribed using Bioscript Reverse Transcriptase (Bioline, UK) and random 
hexamers (Bioline, UK) and 10 mM dNTP mix (dATP, dGTP, dCTP and dTTP, 
Bioline, UK), according to the manufacturer’s instructions. 
Total mRNA in the sample was served as template in reverse transcription 
process. Random hexamers or oligo(dT) bound to its complementary region on 
mRNA and complementary DNA was synthesized by reverse transcriptase using 
dNTP as precursors (Figure 2.8.2.1).  
 
Figure 2.8.2.1 Diagram illustrating the primer annealing. Oligo dT anneals to the 
poly A tail of mRNA  and the cDNA is reversed trancripted by reverse transcritase 
activity (Farrell Jr, 2010a) 
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2.9 Real-Time Polymerase Chain Reaction (RT-PCR) 
 RT-PCR is a fluorescent method that was used to monitor the primers used 
during each PCR cycle. In these studies, the TaqMan® assay was performed using a 
oligonucleotide probe which is labeled with 6-carboxyfluorescein (6-FAM) as a 
reporter dye at 5’ end and a non-fluorescent quencher at 3’ end. This probe binds in 
between the target gene template. The target gene PCR product was synthesized used 
the Taq DNA polymerase with specific primers. During the replication, the 5′ 
exonuclease activity associated with the Taq polymerase cleaves the dye probe, 
removed the 6-FAM from the quencher, resulting in a fluorescent signal. The 
accumulation signals from each cycle reflect gene expression at transcritption level 
(Figure 2.9.1). 
 
Figure 2.9.1 TaqMan® assay for RT-PCR. Reporter probe containing the 
fluorescent reporter and quencher dye is designed to anneal with specific region in 
mRNA. The probe is cleaves during DNA polymerization, allowing reporter dye to 
emit light.(Farrell Jr, 2010b) 
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For procedure, 1 µL of cDNA was mixed with 24 µL of a reaction buffer 
containing Taqman universal PCR mastermix (Applera, UK). All reactions were 
multiplexed with the housekeeping gene 18S, provided as a pre-optimised control 
probe (Applera,  UK) enabling data to be expressed as delta threshold cycle (ΔCT) 
values (where ΔCT = CT of 18S subtracted from CT of gene of interest). The 
reactions of PCR were as follows; 50
0
C for 2 mins, 95
0
C for 10 mins, 44 cycles of 
95
0
C for 15 mins and 60
0
C for 1 min. Measurements were carried out using an ABI 
7500 Sequence Detection System (Applera, UK). 
   
2.10 Microarray technique 
 Microarray is a technique used to detect expression of a set of genes. High 
quality of RNA was used to synthesize cDNA as previously described. cDNA was 
labeled with fluorescent day and hybridized with microarray, according to a  standard 
Affymetrix protocols (Figure 2.10.1). PLA2 mRNA expression was investigated 
using the 219064_AT probe set and the Human Genome U133A DNA microarray 
(Affymetrix).  
 
Figure 2.10.1Diagram illustrating DNA microarray technique (Lamartine, 2006)  
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2.11 Immunohistochemistry 
 Immunohistochemistry is a technique used to identify and localize the protein 
of interest within a tissue section. 
2.11.1 Tissue section 
 Approximately 50 µg of fresh AT was fixed in formalin and embedded in 
paraffin. The tissue section were cut at 3µm thick and mounted on 3-
Aminopropyltriethoxy-silane coated slides. The slides were incubated overnight at 
60
0
C. The sections were then de-paraffinized and rehydrated by soak in 100%Xylene 
for 3 mins twice, followed by 1:1 ratio of 100%Xylene and absolute ethanol for 3 
mins, absolute ethanol 3 mins twice, 95% ethanol 3 mins, 70% ethanol 3 mins and 
50% ethanol for 3 min, respectively. The slides were rinsed with tap water.  
2.11.2 Section blocking 
 The slides were incubated in 1.5% hydrogen peroxide for 20 mins and rinsed 
with tap water. Then the slides were incubated in 1% horse serum (Vectastain 
Universal Elite ABC detection kit, Vector Laboratories, CA, USA)   
2.11.3 Immunohistochemical staining 
 After blocking step, slides were rinsed with 0.05M, pH 7.6 PBS and 
incubated with primary antibody for 2 hr at RT. The slides were then rinsed 3 times 
with 0.05M, pH 7.6 PBS for 3 mins. Tissue sections were incubated with the 
biotinylated secondary antibody for 30 mins, RT and were washed with 0.05M, pH 
7.6 PBS for 5 mins, 3 times. The slides were then incubated with an avidin-biotin 
complex (Vector Elite ABC reagent) for 30 mins and rinsed with PBS for 5 mins. 
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The DAB solution (Menarini Concentrated Substrate Cat. HK153-5K) was freshly 
prepared and applied to each tissue slide. The slides were incubated until a brown 
staining appeared. 
2.11.4 Counter Staining of tissue sections 
 The slides were rinsed with deionized water and counter stained with Mayer’s 
haematoxylin (BDH, Poole, UK) for 1 min and immediately washed with tap water. 
The slides were then dehydrated by immerging in IMS alcohol for 5 mins, followed 
by 100%Xylene for 2 mins and repeated this step with fresh 100%xylene. The slides 
were mounted with a xylene-based mounting agent (DPX; UK).   
2.12 Plasma and serum collection 
 Whole blood was drawn into serum tube, plasma tube containing NaF  for 
fasting blood glucose measurement and plasma tube containing EDTA tube for 
ELISA measurement (BD-vacutainer ®). Serum tube was left at RT for 30 mins to 
allow the blood to clot. All sample tubes were then centrifuged at 600g for 10 mins at 
RT. Supernatant was transfer to sterile 1.5 mL centrifuge tube and kept at -80
0
C. 
 
2.13 Enzyme Linked Immunosorbent Assay (ELISA) 
 Serum or plasma cytokines, LpPLA2 and ox-LDL were measured by using 
the commercial ELISA kits. ELISA analysis was carried out according to the 
manufacturer’s instructions.  
 ELISA is based on antigen-antibody reaction. The antibody of the protein of 
interest was coated in the solid well plate. Samples were then pipetted into the well 
and incubated to allow the antigens in samples bound to the specific antibody. After 
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incubation, the reaction plates were washed with washing buffer, according to the 
relevant procedures in order to remove excess antigens. The peroxidase conjugated 
secondary antibody was added to detect the immobilized immune complex. After 
incubation, the plates were then washed with washing and subsequently added the 
substrate, TMB, to produce color. The color product was measured by microplate 
reader within 30 mins.   
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 3 :  PLA2 Expression in Human Adipose Tissue 
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3.1 Introduction 
Lipoprotein-associated phospholipase A2 (LpPLA2) is a member of the 
phospholipase A2 super family of enzymes. These enzymes hydrolyse polar 
phospholipids, such as those generated during the oxidation of low density 
lipoprotein (Ox-LDL), which results in the production of pro-inflammatory 
mediators, such as lysophosphatidylcholine and oxidised fatty acids (Rosenson & 
Stafforini, 2012; Toth et al., 2010; Zalewski, Nelson, Hegg, & Macphee, 2006). 
Whilst secreted soluble PLA2 (sPLA2) is known to increase arterial inflammation, 
other members of the family, such as cytosolic calcium dependent PLA2 (cPLA2) 
and calcium independent PLA2 (iPLA2), also appear to contribute to inflammatory 
processes through production of lipid mediators (Toth et al., 2010). 
Recent interest in LpPLA2 has arisen due to a number of epidemiological 
studies that have shown circulating LpPLA2 to be up-regulated in conditions of 
inflammation and cardiovascular disease (CVD) (Khakpour & Frishman, 2009; 
Kinney et al., 2011; Oei et al., 2005; Winkler et al., 2007). In contrast, limited 
studies, to date, have examined circulating LpPLA2 in patients with T2DM, although 
a recent study has highlighted LpPLA2 levels as being positively correlated with 
body mass index (BMI), as well as triglycerides (TG), low density lipoprotein (LDL) 
and high density lipoprotein (HDL). Furthermore, elevated LpPLA2 levels have been 
associated with predicting T2DM (Maria Waegner et al., 2011; Nelson et al., 2012), 
although other reports have not been conclusive (Constantinides et al., 2011; Nelson 
et al., 2011). Much of the research, to date, has centred on CVD and the role of the 
macrophage as a major source of LpPLA2, although other cells types are also noted 
to express LpPLA2 including T lymphocytes, mast cells and hepatocytes (W.-Y. 
Wang et al., 2010; M. Yang et al., 2010; Zalewski et al., 2006). Previous in vitro 
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studies, using monocytes, have specifically examined the stimulatory effect of Ox-
LDL on LpPLA2 activity, which indicates the potential influence of LpPLA2 on 
arterial inflammation (W.-Y. Wang et al., 2010); whilst in vivo studies have shown 
that Ox-LDL are significantly associated LpPLA2 in carotid endarterectomy (CEA) 
tissues (Vickers et al., 2009). 
LpPLA2 appears to represent a biomarker of CVD and/or T2DM risk and 
previous LpPLA2 studies have considered the rationale for its correlation with 
metabolic disease. In particular, LpPLA2 activity may arise as a consequence of 
ectopic fat deposition, raising circulating lipids, with an increase in LpPLA2 activity 
triggering production of pro-inflammatory mediators (Gomes et al., 2009; Silva, 
Mello, & Damasceno, 2011). Alternatively, increased macrophage activity noted 
through raised souble-CD14 levels may arise in response to an inflammatory insult, 
such as metabolic endotoxaemia (Al-Attas et al., 2009; Harte et al., 2010). Clinical 
studies have implicated gut-derived endotoxin as a “primary insult” to activate the 
inflammatory state, contributing to metabolic disease, with current cross-sectional 
and longitudinal data showing elevated systemic endotoxin levels in conditions of 
obesity, T2DM, coronary artery disease, fatty liver disease and high fat diet (Baker et 
al., 2009; Creely et al., 2007). Taken together, both circulating endotoxin and lipids 
may contribute to circulating LpPLA2 activity. However, whilst it seems clear that 
LpPLA2 studies implicate the interrelationships between AT, inflammation and 
insulin resistance as important, no study to date has examined human AT and the role 
of the adipocyte as an additional factor influencing the regulation of PLA2 isoforms. 
Therefore the aim of this chapter was to examine the influence of metabolic state and 
AT depot on PLA2 expression and its isoforms.  
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3.2 Materials and Methods 
3.2.1 Subjects: Tissue collection 
For this study, a female cohort was utilised, consisting of lean, (Age: 44.4±6.2yr; 
BMI: 22.1±0.2 kg/m
2
, n=26) overweight (Age: 45.4±12.3yr; BMI: 26.9±0.2 kg/m
2
, 
n=22), obese (Age: 49.0±9.1yr; BMI: 33.7±0.7 kg/m
2
, n=24) and T2DM subjects 
(Age: 53.0±6.13yr; BMI: 44.2±1.8 kg/m
2
, n=14). Paired human abdominal 
subcutaneous (Abd Sc) and omental (Om) AT biopsies were taken from a sub-group 
of patients undergoing elective surgery who were either lean (age 43.6±6.2yr; BMI; 
22.5±0.8 kg/m
2
; n=9), overweight (age; 47.5±11.5yr; BMI: 27.4±0.4 kg/m
2
; n=10) or 
obese (age; 48.1±8.5yr; BMI: 34.0±1.1 kg/m
2
; n=5) and the tissues flash frozen 
immediately. All subjects had their height, weight and BMI measurements taken 
using standard equipment. Detailed medical drug histories were taken and those 
subjects on medication considered to alter inflammatory status were excluded, 
including the thiazolidinediones. Ethical approval was obtained from the local 
research ethics committee and all patients gave written consent. Fasted blood 
samples were taken prior to surgery and serum levels were analysed as detailed 
below.  
3.2.2 RNA extraction and semi-quantitative RT-PCR 
RNA was extracted from samples using RNeasy lipid tissue kit (Qiagen,West 
Sussex, UK) according to the manufacturer’s instructions. Extraction was followed 
by a DNase digestion step to remove any contaminating genomic DNA. RNA was 
quantitated using the Nanodrop ND-1000 Spectrophotometer (LabTech, East Sussex, 
UK) and 200 ng of RNA from each sample was reverse transcribed using Bioscript 
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Reverse Transcriptase (Bioline, London, UK) and random hexamers, according to 
the manufacturer’s instructions. Quantitative real-time PCR was performed with pre-
designed gene specific Taqman probes and primers (Applied Biosystems, Paisley, 
UK, LpPLA2; Hs00173726_m1, cPLA2; Hs00233352_m1, iPLA2; Hs00185926_m1 
and EMR1; Hs00173562_m1) in a reaction mix containing TaqMan universal PCR 
master mix (Applied Biosystems, Paisley, UK). All reactions were multiplexed with 
the housekeeping gene 18S, provided as a pre-optimised control probe (Applied 
Biosystems, Paisley, UK) enabling data to be expressed as delta threshold cycle 
(ΔCt) values (where ΔCt = Ct of 18S subtracted from Ct of gene of interest). 
Measurements were carried out in triplicate for each sample. 
3.2.3 Microarray analysis 
 RNA from the AT samples was used for gene expression analysis with the 
Human Genome U133A plus 2.0 DNA microarrays (Affymetrix, Santa Clara, CA). 
A detailed methodology of the principles behind microarray is cited in Chapter 2. In 
brief for this study, gene expression was analyzed using the Human Genome U133A 
DNA microarray (Affymetrix). Preparation of cRNA and hybridization to DNA 
microarrays was performed according to standard Affymetrix protocols, as 
previously described (Saiki et al., 2009, Anveden et al., 2012). PLA2 mRNA 
expression was investigated using the 219064_AT probe set.  
3.2.4 Protein determination and Western blot analysis  
Human AT was homogenized and suspended in Phosphosafe™ extraction 
buffer (Novogen ®, Merck, Germany). Protein concentrations
 
were determined using 
the Bio-Rad Detergent Compatible protein
 
assay kit (Bio-Rad Laboratories, 
Hercules, CA) (Bradford, 1976). Western
 
blot analysis was performed using a 
  
61 
 
method previously described (Towbin, Staehelin, & Gordon, 1979). In brief, 40 µg of 
protein were loaded on to a denaturing polyacrylamide gel (7.5%) (GeneFlow, 
Leicestershire, UK). Protein expression of cPLA2 (1:100,
 
Cell Signaling) and iPLA2 
(1:500, Sigma) was assessed using rabbit
 
monoclonal antibodies. Equal protein 
loading was confirmed by
 examining β actin protein expression. No statistical 
difference was observed in
 β actin expression for all samples analyzed. A 
chemiluminescent detection
 
system, ECL/ECL
+
 (Amersham Pharmacia Biotech, 
Little Chalfont,
 
UK), enabled visualization of bands, whereas intensity was 
determined
 
using densitometry (Genesnap, Syngene, UK). 
3.2.5 Immunohistochemistry  
Tissue samples were obtained from Medical Solutions and incubated with 
primary polyclonal LpPLA2 antibody (R&D Systems, UK) in a dilution of 1:100. 
Sections were developed using peroxidase substrate kit VIP® (Vector Laboratories 
Ltd. UK) for LpPLA2. In order to demonstrate specific binding, the primary antibody 
was omitted for negative control for LpPLA2 independently. A detailed methodology 
of immunohistochemistry is outlined in Chapter 2. 
3.2.6 Cell cultures and human lipoprotein treatment 
Abdominal subcutaneous adipose tissue (AbdSc AT) was digested, as 
previously described and detailed in Chapter 2, to isolate pre-adipocytes (McTernan 
et al., 2003). In brief, approximately 50-100 mg of AbdSc AT was finely chopped 
and incubated in collagenase (2 mg/ml; Worthington Biochemical, USA) for 30 min 
at 37
o
C. Following centrifugation and several washing stages, the stromal vascular 
pellet was obtained. 
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 The AbdSc pre-adipocytes were grown in 6-well plates to confluence in 
phenol red-free Dulbecco’s modified Eagle’s medium (PRF-DMEM F-12) 
containing 10% bovine serum, penicillin (100 U/ml), streptomycin (100 μg/ml) and 
transferrin (5 μg/ml) at 370C, 5%CO2 incubation until confluent.  To undertake cell 
differentiation, AbdSc pre-adipocytes were maintained in promocell pre-adipocyte 
differentiation media (PromoCell, Germany) for 48 hr and, following this time 
period, the cells were maintained in the promocell adipocyte nutrition media 
(PromoCell, Germany) for fourteen days, with media changes every two days. 
3.2.7 Statistical Analysis 
Data analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) version 18.0 for Windows (SPSS UK Ltd, UK).  Student t-test was 
performed comparing PLA2 gene expression among lean versus obese subjects. 
Analysis of variance (ANOVA) with Bonferroni correction controlling for type 1 
error was used to compare mRNA and protein expression among groups with 
varying degrees of adiposity and T2DM status (adjusted P-value < 0.017, considered 
as statistically significant).  
Significance of gene expression between AbdSc and Om AT were 
determined by paired T-test. Determination of correlations in gene expression 
analysis and variables of interest were performed using Pearson’s correlation 
coefficient for normally distributed variables and Spearman’s rank correlation 
coefficient for variables that were non-Gaussian (LpPLA2). Significance for these 
tests was set at P<0.05. 
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3.3 Results 
3.3.1 PLA2 microarray expression profile in adipose tissue. 
The microarray was performed using 20 probes corresponding to 4 
isoenzymes in the platelet activating factor acylhydrolase family (PLA2G7, PAF 
AH2, PAF AH 1B1and PAH 1B2), 3 isoenzymes in the Ca
2+
 dependent PLA2 family 
(PLA2 G4A, PLA2 G4C and PLA2 G4D), 4 isoenzymes in Ca
2+
 independent PLA2 
family ( PLA2 G6, PNPLA2, PNPLA4 and PNPLA5), 9 isoenzymes in secretory 
PLA2 family (PLA2 G1B, PLA2 G2A, PLA2 G2D, PLA2 G2E, PLA2 G2F, PLA2 
G5, PLA2 G10, PLA2 G12A and  PLA2 G12B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1.1 Microarray data analysis of PLA2 gene family in AbdSc AT. The 
bars represent a ratio between intensity signal in AbdSc AT taken from lean and 
obese. The significant fold change was assessed by unpaired t test (*P<0.05) 
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Significant changes in expression were noted for PLA2 G7 (LpPLA2) and 
PLA2 G6 (iPLA2) in AbdSc AT taken from obese subjects compared with AbdSc 
AT taken from lean individuals. PLA2 G6 showed decreased expression (P<0.05) in 
contrast to PLA2 G7, which showed upregulation (P<0.05) (Fig 3.4.1.1). No 
difference in expression of gene tested in this experiment were observed in Om AT 
(Fig 3.3.1.2). The significant changes in microarray data were further verified by RT-
PCR and Western blot analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1.2 Microarray data analysis of PLA2 gene family in Om AT. The 
bars represent a ratio between intensity signal in Om AT taken from lean and obese. 
Student t test was used to test the significant difference between lean and obese. 
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3.3.2 Comparative gene and protein expression of PLA2 between AbdSc and 
Om AT taken from lean, overweight and obese subjects; microarray data 
verification. 
The mRNA and protein level of LpPLA2 (gene PLA2G7) was significantly 
higher in the AbdSc AT than the Om AT in obese subjects (P<0.05). The expression 
of LpPLA2 was raised, but not significantly, in the overweight or obese AT samples 
(Fig 3.3.2.1A). Analysis of LpPLA2 western blot indicated that increasing adiposity 
alone did not increase LpPLA2 protein level (Fig 3.3.2.1B).  
 
 
 
 
 
 
 
Figure 3.3.2.1. mRNA and Protein expression of LpPLA2 in AbdSc and Om AT from 
lean (n=9), overweight (n=10) and obese (n=5) non-diabetic subjects: (A) AbdSc 
and Om AT LpPLA2 mRNA expression (PLA2G7). (B) LpPLA2 protein levels. All 
RT-PCR and Western blot results were standardized to lean AbdSc AT. The 
difference in expression between AbdSc and Om AT was assessed by paired t test (*, 
P<0.05). Unpaired t test with bonferroni adjustment (correction for significant 
P<0.017) was performed to compare expression levels across adiposity.The mean of 
expression level of lean AbdSc AT was calculated and individual values measured in 
lean overweight and obese are normalized to this value.  
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The mRNA level of cPLA2 (gene PLA2G4A) was significantly higher in Om 
AT compared with AbdSc AT taken from lean subjects (P<0.001); whilst there was 
no significant difference in cPLA2 gene expression between Abd Sc and Om AT 
depots in either overweight or obese subjects.  However within the Abd Sc AT depot, 
cPLA2 mRNA level was significantly increased in both the overweight (P<0.05) and 
obese subjects (P<0.05). In contrast, in the Om AT depot, cPLA2 mRNA level was 
significantly decreased in the obese subjects (P<0.001; Fig 3.3.2.2 A). Subsequent 
cPLA2 protein expression analysis confirmed the noted gene expression findings 
within Abd Sc AT, increased in overweight and obese subjects (P<0.001 and P<0.01, 
respectively), whilst, again, Om AT decreased in the obese subjects (P<0.01; Fig 
3.3.2.2 B 
 
  
 
 
Figure. 3.3.2.2. mRNA and Protein expression of cPLA2 in AbdSc and Om AT 
from lean (n=9), overweight (n=10) and obese (n=5) non-diabetic subjects: (A) 
AbdSc and Om AT cPLA2 mRNA expression (PLA2G4). (B) AbdSc and Om AT 
cPLA2 protein expression. All RT-PCR and Western blot results were standardized 
to lean AbdSc AT. The difference in expression between AbdSc and Om AT was 
assessed by paired t test (*, P<0.05; ***, P<0.001). Unpaired t test with bonferroni 
adjustment (correction for significant P<0.017) was performed to compare mRNA 
levels across adiposity (#, P<0.017; ###, P<0.001, each group vs. lean Sc AT: 
P<0.01; †††, P<0.001, each group vs. lean Om AT). The mean of expression level 
of lean AbdSc AT was calculated and individual values measured in lean overweight 
and obese are normalized to this value.  
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There was no difference in iPLA2 (gene PLA2G6) gene expression between 
paired Abd Sc and Om AT and no noted effect on adiposity (Lean, Abd Sc: 
11.85±0.12∆Ct; Om: 12.18±0.20∆Ct; Overweight, Abd Sc: 11.65±0.17∆Ct Om: 
12.141±0.16∆Ct; Obese, Abd Sc: 12.02±0.26∆Ct Om: 12.62±0.15∆Ct; Fig 3.4.2.3 
A). Protein analysis showed moderately significant increases in iPLA2 in Om AT 
compared with Abd Sc AT from all groups (P<0.05; Fig 3.4.2.3 B), although there 
were no significant differences in iPLA2 protein levels between lean, overweight and 
obese in both Abd Sc and Om AT (Fig 3.3.2.3 B).  
 
 
 
 
 
 
 
 
 
 
Figure. 3.3.2.3. mRNA and Protein expression of iPLA2 in AbdSc and Om AT 
from lean (n=9), overweight (n=10) and obese (n=5) non-diabetic subjects: (A) 
AbdSc and Om AT iPLA2 mRNA expression (PLA2G6); (B) AbdSc and Om AT 
iPLA2 protein expression. All RT-qPCR and Western blot results were standardized 
to lean AbdSc AT. The difference in expression between AbdSc and Om AT was 
assessed by paired t test (*, P<0.05; ***, P<0.001). Unpaired t test with bonferroni 
adjustment (correction for significant P<0.017) was performed to compare mRNA 
levels across adiposity. The mean of expression level of lean AbdSc AT was 
calculated and individual values measured in lean overweight and obese are 
normalized to this value 
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3.3.3 T2DM status influences the expression of PLA2 isoforms in Adipose tissue. 
The LpPLA2 mRNA expression in T2DM AbdSc AT was approximately 5 
fold higher than the non-T2DM AbdSc AT (P<0.001). Similarly, the Om AT 
LpPLA2 mRNA expression was higher in the T2DM group, at approximately 2 fold 
greater than the non-T2DM group (P<0.01; Fig 3.3.3.1 A). Further analysis of 
LpPLA2 protein expression confirmed the mRNA findings (Fig 3.3.3.1 B).  These 
data suggest that LpPLA2 gene and protein expression appear to be up-regulated 
under T2DM conditions.  
 
 
 
Figure 3.3.3.1 Comparison of mRNA and protein expression of tissue LpPLA2 
between non-T2DM and T2DM: (A) LpPLA2 mRNA expression in AbdSc and 
Om AT compared between non-diabetic (n=24) and T2DM subjects (n=13). (B), 
LpPLA2 protein expression in AbdSc taken from lean, obese and obese T2DM. All 
RT-PCR and Western blot results were standardized to lean AbdSc AT. The 
difference in expression between AbdSc and Om AT was assessed by paired t test (*, 
P<0.05; ***, P<0.001). Unpaired t test with bonferroni adjustment (correction for 
significant P<0.017) was performed to compare mRNA levels across adiposity (#, 
P<0.017; ###, P<0.001, each group vs. lean Sc AT:  †, P<0.017; ††, P<0.01; †††, 
P<0.001, each group vs. lean Om AT). The mean of expression level of lean AbdSc 
AT was calculated and individual values measured in lean overweight and obese are 
normalized to this value. 
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There were no significant differences in mRNA levels of cPLA2 and iPLA2 
between the non-diabetic and T2DM groups, in either AbdSc AT or Om AT (Fig 
3.3.3.2 A and B, respectively). This data indicated that among of PLA2 expression 
evaluated by microarray, RT-PCR and western blot, LpPLA2 was the only isoform 
that showed the higher expression in T2DM compared to non T2DM subjects. 
 (A) 
 
(B) 
 
 
 
Figure 3.3.3.2 Comparison of mRNA of tissue cPLA2 and iPLA2 between non-
T2DM and T2DM: (A) cPLA2 mRNA level in AbdSc and Om AT compared 
between non-diabetic (n=24) and T2DM subjects (n=13). (B), iPLA2 mRNA level in 
AbdSc and Om AT. Unpaired t test with bonferroni adjustment (correction for 
significant P<0.017) was performed to compare mRNA levels between non T2DM 
and T2DM.  
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3.3.4 Factors that influence mRNA and protein expression of LpPLA2 in AbdSc 
and Om AT 
To investigate the importance of the macrophage as an active source of 
LpPLA2 in AT, the relationship between the macrophage specific marker, EMR1, 
and LpPLA2 mRNA expression was examined. The results highlighted that there 
was no significant correlation between EMR1 and LpPLA2. Taken together, these 
data support the concept that the increased LpPLA2 mRNA and protein expression 
observed in the AbdSc AT taken from T2DM subjects appears adipocyte derived 
(Figure 3.3.4.1). However, a significant, positive correlation between EMR1 and 
LpPLA2 was noted in Om AT (r=0.534, P=0.049), which has previously been 
reported as an active site of macrophage activity.  
         
Figure 3.3.4.1 Factors that influence mRNA and protein expression of LpPLA2: 
Correlation analysis using Spearman’s correlation coefficient with line of best fit 
between delta Ct values of LpPLA2 mRNA and macrophage specific marker, EMR1, 
in AbdSc AT (A) and Om AT (B) from T2DM subjects were tested. Significant 
correlation was set at P<0.05.  
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Immunohistochemistry showed the expression of LpPLA2 in the mature 
adipocytes taken from lean non-T2DM human AbdSc AT (Fig 3D (i)). LpPLA2 was 
observed to be concentrated in the adipocyte as denoted by the brown staining 
observed around each cell. Placenta tissue was used as a positive control for LpPLA2 
expression with positive brown staining also shown (Fig 3..4.2 (iii)), with appropriate 
negative staining noted in both tissue sections (Fig 3.4.4.2 (ii) (iv)).  
 
 
Figure 3.3.4.2 LpPLA2 expression in adipose tissue: Immunohistochemical 
expression of LpPLA2 detailed as follows: (i) AbdSc AT LpPLA2 positive staining 
(brown)  (ii) negative control in AbdSc with omission of primary antibody (iii) 
positive control in placenta for LpPLA2 (iv) negative control in placenta with 
omission of primary antibody (i-iv magnification x200). 
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3.4.5 LpPLA2 expression in primary cell culture and human pre-adipocyte cell 
line. 
 The mRNA and protein expression of LpPLA2 was observed in both the 
human primary culture and the human adipocyte cell line, Chub S7, indicating 
adipocyte produced LpPLA2. The expression of LpPLA2 was not different between 
pre adipocyte and differentiated adipocyte at day 14 in both primary cells and cell 
line (Fig 3.3.4.3). 
 
 
 
 
 
Figure 3.3.4.3 LpPLA2 expression in primary cell culture and cell line: (A), 
LpPLA2 mRNA expression. (B), protein expression in human primary culture (n=3) 
and human adipocyte cell line. Significant changes in expression between primary 
and cell culture, and pre adipocyte and differentiated adipocyte, were tested by 
student t test. 
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3.5 Discussion 
Obesity is a condition that activates inflammation in adipose tissue, leading to 
high risk of T2DM and atherosclerosis (Gustafson, 2010; S. J. Kim et al., 2014; Olza 
et al., 2014). Our previous studies have shown that increasing adiposity and T2DM 
status contribute to an increased inflammatory response in human Epicardial AT 
(Baker et al., 2009) and AbdSc AT (Harte et al., 2013b). However, no study, to date, 
has examined LpPLA2 - a known mediator of inflammation in CVD - directly in 
human AT (Khakpour & Frishman, 2009; Kinney et al., 2011; McCullough, 2009; 
Toth et al., 2010). As weight gain heightens the inflammatory state, this may have 
specific relevance for cPLA2 which is known to be phosphorylated by p42/44 
MAPKs, p38 MAPK and JNK, highlighting its potential inflammatory role (X. Wang 
et al., 2008). The iPLA2 isoform is also considered as a pathogenic inflammatory 
marker in vascular tissue, leading to increased oxidative stress and inflammation 
(Zhongwen Xie et al., 2010). Thus, this is the first study to examine the comparative 
and differential changes in expression of all PLA2 isoforms in AbdSc and Om AT 
across adiposity with or without T2DM.  
This current study showed that upon examining all PLA2 isoforms in AbdSc 
and Om AT, in lean and obese subjects, two isoforms appeared to be significantly 
altered in AbdSc AT. Specifically, PLA2 G7 (LpPLA2) and PLA2 G6 (iPLA2) were 
significantly altered with increasing adiposity. However, both mRNA and protein 
data showed a slightly increased, but not significant, LpPLA2 AbdSc AT mRNA 
expression whilst iPLA2 mRNA expression in this depot remained unchanged. 
Between depots analysis indicated LpPLA2 mRNA expression appeared 
significantly higher in AbdSc AT than in Om AT, independent of adiposity.  
  
74 
 
Further studies examined gene expression changes comparing non-diabetic 
and T2DM AT samples. These studies highlighted dramatic changes in LpPLA2 
gene expression in Abd Sc AT, with a 5 fold increase noted in LpPLA2 from non-
diabetic AT compared with T2DM AT. In a similar fashion, Om AT LpPLA2 mRNA 
expression increased 2 fold. This data also showed that LpPLA2 expression was 5 
fold higher in Abd Sc AT from T2DM subjects compared with Om AT from the 
same subjects. Due to such a significant change, and the knowledge that 
macrophages are a specific source of LpPLA2 which are known to be increased in 
obesity and T2DM, our studies utilised a specific macrophage marker, EMR1, to 
examine the relationship with LpPLA2 (Harford, Reynolds, McGillicuddy, & Roche, 
2011; Khazen et al., 2005). This was specifically to identify how much contribution 
marcophages may make to the data observed in human AT. 
From our studies, there was no correlation with EMR1 and LpPLA2 in 
AbdSc AT, in contrast to Om AT, suggesting that the changes observed in AbdSc 
AT LpPLA2 mRNA and protein expression appear to arise from the adipocyte itself. 
Such findings are in accord with previous studies examining other adipocyte 
inflammatory factors which also expressed in macrophages; for these studies other 
selective macrophage markers were utilised, such as CD45 and CD68, which again 
were unable to show a correlation in abdominal AT (Baker et al., 2009; McGee et al., 
2011; McTernan et al., 2003) further supporting the concept that LpPLA2 changes 
observed were derived from the adipocyte and not the macrophages. 
To further identify that the adipocyte itself was an important source of 
LpPLA2, immunohistochemical analysis was undertaken. Immunohistochemical 
staining highlighted that there was LpPLA2 in AT as denoted by brown staining 
accumulated around adipocyte cytoplasm attached to the adipocyte plasma 
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membrane, confirming that LpPLA2 protein is abundantly expressed in adipocyte. 
However it should still be noted thought that despite these data indicating LpPLA2 
appears to be derived from AbdSc adipocytes, it should be stated that macrophages 
may still play a role in LpPLA2 activation within AT under different circumstances 
then in conditions or changing adiposity or T2DMs. Also it would be important to 
note that how circulating macrophages may be influenced in atherosclerotic disease 
may be very different.   
As we are providing data as to the source of LpPLA2 within the adipocyte 
additional studies were undertaken to examine mRNA LpPLA2 was in both, primary 
human, AbdSc pre-adipocyte cell cultures and a secondary, human, adipocyte cell 
line, Chub S7 cells. Interestingly, there was no differences noted between LpPLA2 
mRNA expression between pre-adipocyte and differentiated adipocyte at day 14 
either primary or cell line cultures. This in vitro analysis suggested that LpPLA2 
appears consistently present pre- and post- differentiation. The role LpPLA2 may 
have in adipocyte differentiation was not specifically investigated as the intervening 
days were not studied, which may have caused a change in LpPLA2 expression. 
However taken together, the ex vivo adipose tissue data and in vitro studies indicate 
LpPLA2 is expressed in human adipocytes.    
Further analysis of cPLA2 indicated that there was a significant increase in 
mRNA expression with increasing adiposity in AbdSc AT, which was confirmed by 
protein analysis. In contrast, cPLA2 mRNA expression in Om AT was 2 fold higher 
in lean individuals compared with Abd Sc AT, which then reduced as adiposity 
increased, in an apparent step-wise opposing manner to cPLA2 expression in AbdSc 
AT. A similar but less pronounced change in cPLA2 protein expression was also 
noted across AbdSc and Om AT with increasing adiposity. Analysis of iPLA2 
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mRNA expression showed no significant change with adiposity in either Abd Sc or 
Om AT and only iPLA2 protein expression showed a modest increase in Om AT 
compared with Abd Sc AT with weight gain; this was lost in the obese group. 
However, there were no significant changes in cPLA2 and iPLA2 mRNA level in 
both AbdSc AT and Om AT between non T2DM and T2DM, indicating that diabetic 
status did not influent the expression of cPLA2 and iPLA2. In the case of cPLA2 and 
iPLA2, these isoforms are less well described and their functions in adipose tissue 
requires much more study compared with our understanding of LpPLA2’s functions 
in tissues. 
In summary, these studies highlight that human AT and the adipocyte itself 
appears to represent an active source of LpPLA2. LpPLA2 expression is raised in 
Abd Sc AT from obese non-diabetic subjects, which is further enhanced in the 
T2DM state. Furthermore as LpPLA2 can be secreted into blood circulation, it would 
be important to understand the both the direct association LpPLA2 may have with 
other metabolic makers, as the over-expression of oxidized fatty acid due to the 
increased LpPLA2 production in obesity and T2DM may promote further 
inflammation in T2DM and pathogenesis of complications such as atherosclerosis. 
As such studying the association circulating LpPLA2 in metabolic disease may help 
understand what factors influence how adiposity and T2DM increase the risk of 
cardiovascular disease. 
  
 
 
 
 
 
 
CHAPTER 4 : The Systemic Relationships Between 
LpPLA2 and Metabolic Markers. 
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4.1 Introduction 
Within the PLA2 family, LpPLA2 is the only secretory protein whilst cPLA2 
and iPLA2 are both cytosolic proteins. The major source of LpPLA2 in the blood has 
been considered to arise from the monocyte derived macrophage, T lymphocyte and 
mast cells (Bao et al., 2008; Zhongwen Xie et al., 2010). LpPLA2 itself is known to 
bind to lipoproteins in the circulation, especially with LDL in normolipidemic 
subjects, whilst the minority of circulating LpPLA2 is also associated with HDL 
(Rosenbaum et al., 2012; Rubinstein & Izkhakov, 2011). Recently, studies have 
suggested that measuring circulating LpPLA2 could be viewed as a new marker for 
monitoring atherosclerosis (A. Cai et al., 2013; Mangili et al., 2014; Tousoulis, 
Papageorgiou, Androulakis, & Stefanadis, 2013). However, the cause and effect role 
of LpPLA2 in atherosclerosis remains unclear, part due to the fact that the anti-
atherogenic and pro-atherogenic function of LpPLA2 has produced conflicting 
reports (S. B. Li et al., 2013; Rosenson & Hurt-Camejo, 2012; Rosenson & 
Stafforini, 2012; Tousoulis et al., 2013). LpPLA2 has the ability to remove oxidized 
phospho-lipids (PLs) and degrade platelet activating factor (PAF), stopping the 
oxidative process in LDL and HDL, resulting in anti-atherosclerosis and anti-
inflammation.  
However at the same time, LpPLA2 can produce lysophosphatidylcholine 
and oxidized free fatty acid, which both exhibit pro-atherogenic effects. Moreover, 
activation of LpPLA2 can produce arachidonic acid and consequently accumulate 
pro-inflammatory enzymes, such as active cyclooxygenase (COXs) and lipoxygenase 
(LOXs) which promote inflammation. Specifically COX2 is the enzyme responsible 
for synthesizing pro-inflammatory prostaglandins, and is the target of non-steroidal 
anti-inflammatory drugs (ibuprofen, aspirin) and COX2 inhibitors (Celebrex®) 
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(Aldrovandi & O'Donnell, 2013). Whilst lipoxygenases are also expressed in many 
tissues, including adipose tissue and 15-lipoxygenase appears to be able to generate 
both pro- and anti-inflammatory metabolites. 15-lipoxygenase in obesity promotes 
the onset of metabolic dysfunction and therapeutics against 15-lipoxygenase may be 
able to treat metabolic dysfunction (Chakrabarti et al., 2011; Cole, Kuhn, et al., 2012; 
Cole, Morris, Grzesik, Leone, & Nadler, 2012). 
 The following studies highlight the proatherogenic function of LpPLA2. In a 
prospective cohort study, expression of LpPLA2 and lysophosphatidylcholine, 
LpPLA2 was identified to be higher in plaques taken from patients undergoing 
carotid endarterectomy, compared with patients without any cardiovascular event 
(Sun et al., 2001). Furthermore the treatment of darapladib, a PAF-acetylhydrolase 
(AH) inhibitor, in a diabetic/hypercholesterol swine model markedly reduced the 
lysophosphatidylcholine content in lesion and mitigated the development of 
atherosclerosis (Birbes et al., 2000). In contrast in other studies such as using the 
overexpression model by human LpPLA2 gene transfected apoliprotein E (apoE) 
-/-
 
mice an anti-atherogenic effect was observed. The reduction of atherogenic lesions 
was more observed in male mice following gene transfer (Martinez & Moreno, 
2001). The conflicting reports demonstrate that LpPLA2 might be involved in 
complementary or opposite pathways in atherosclerosis, the understanding of 
expression, function and regulation of LpPLA2 in specific tissue and diseases state in 
different species appears importance as well as the potential disease state where 
LpPLA2 function may alter.   
However, despite expression evidence there is still no clear evidence of how 
LpPLA2 from the adipocyte plays a role on atherosclerosis. Previous analysis has 
indicated that there is higher expression of LpPLA2 in adipose tissue taken from 
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obese and T2DM subjects compared with lean, suggesting a potential pro-
atherogenic role for LpPLA2 in subjects with T2DM. However to understand the 
influence of metabolic state further on circulating LpPLA2 (with an appreciable 
quantity perhaps being derived from adipose tissue in an increased metabolic 
dysfunctional state), the correlation between serum LpPLA2 and circulating 
metabolic markers were studied. Furthermore the association between LpPLA2 
expressed in adipose tissue and inflammatory makers such as IL6, COX2 and 15-
LOX were examined to understand how local inflammation derived from adipose 
tissue may impact and relate to circulating LpPLA2 in different metabolic states. 
Finally in vitro studies were undertaken to assess how ox-LDL a pro-inflammatory 
factor may influence LpPLA2 and inflammatory markers in a closed adipocyte 
culture system.  
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4.2 Materials and methods 
4.2.1 Subjects: Serum and tissue collection 
 Fasting blood samples were taken from a female cohort, consisting of lean, 
(Age: 44.4±6.2yr; BMI: 22.1±0.2 kg/m
2
, n=26) overweight (Age: 45.4±12.3yr; BMI: 
26.9±0.2 kg/m
2
, n=22), obese (Age: 49.0±9.1yr; BMI: 33.7±0.7 kg/m
2
, n=24) and 
T2DM subjects (Age: 53.0±6.13yr; BMI: 44.2±1.8 kg/m
2
, n=14). All subjects had 
their height, weight and BMI measurements taken using standard equipment. 
Detailed medical histories were taken and those non-diabetic subjects on medication 
considered to alter inflammatory status were excluded. In T2DM patients medical 
histories were taken. Ethical approval was obtained from the local research ethics 
committee and all patients gave written consent. Fasted blood samples were taken 
prior to surgery and serum levels were analysed as detailed below.  
4.2.2. In vivo assessment of the biochemical profile 
 Fasting blood samples were collected from participating subjects and lipid 
profiles and fasting plasma glucose were determined using routine laboratory 
methods, undertaken in the biochemistry laboratory, at University Hospital Coventry 
and Warwickshire. In brief, the routine blood tests included glucose and a full 
cholesterol profile (TGs, HDL and LDL), as noted in Table 4.3.1.1. Ox-LDL and 
LpPLA2 were measured by ELISA (Mercodia Oxidized LDL ELISA, Sweden; intra-
assay percentage coefficient of variation (CV) % = 6.4; inter assay % CV = 7.4) and 
R&D Systems Human PLA2G7/PAF-AH/LpPLA2 (Quantikine ELISA, UK; intra-
assay % CV = 6.8, inter-assay % CV = 9.6). Insulin measurements were performed 
by a solid-phase enzyme amplified sensitivity multiplex immunoassay (Millipore, 
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U.K.), and glucose was measured by a glucose oxidase method (YSL 200 STAT 
plus).  
4.2.3 Analysis of circulating endotoxin levels 
 Serum endotoxin was analysed using a commercially available QCL-1000 
LAL End Point Assay (Lonza, NJ). The assay, and the CV values are noted, for the 
intra-assay CV = 3.9±0.46% and inter-assay CV = 9.6±0.75%, this assay has further 
been validated in our laboratory, as detailed previously (Creely et al., 2007; Harte et 
al., 2012). 
4.2.4 RNA extraction and quantitative RT-PCR  
RNA was extracted from samples using RNeasy lipid tissue kit (Qiagen, UK) 
according to the manufacturer’s instructions. Extraction was followed by a DNase 
digestion step to remove any contaminating genomic DNA. RNA was quantitated 
using the Nanodrop ND-1000 Spectrophotometer (LabTech, UK) and 200ng of RNA 
from each sample was reverse transcribed using Bioscript Reverse Transcriptase 
(Bioline, UK) and random hexamers, according to the manufacturer’s instructions. 
Quantitative real-time PCR was performed with pre-designed gene specific Taqman 
probes and primers (Applied Biosystems, UK, LpPLA2; Hs00173726_m1, cPLA2; 
Hs00233352_m1, iPLA2; Hs00185926_m1 and EMR1; Hs00173562_m1) in a 
reaction mix containing TaqMan universal PCR master mix (Applied Biosystems, 
UK). All reactions were multiplexed with the housekeeping gene 18S, provided as a 
pre-optimised control probe (Applied Biosystems, UK) enabling data to be expressed 
as delta threshold cycle (ΔCt) values (where ΔCt = Ct of 18S subtracted from Ct of 
gene of interest). Measurements were carried out in triplicate for each sample. 
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4.2.5 Cell cultures and human lipoprotein treatment 
Human Chub S7 cells were maintained in Growth media, comprised of 
Dulbecco’s modified Eagle’s medium (DMEM/F12) with supplement and 10% FBS, 
20U/ml penicillin/Streptomycin and transferrin at 37
0
C and 5% CO2 incubation. The 
cells were grown until confluent and subsequently differentiated (Promocell, UK). 
Differentiated adipocytes were incubated in DMEM, without FBS, overnight at 37
0
C 
and 5% CO2; the cells were treated with Ox-LDL (100 µg/mL; Kalen Biomedical, 
USA) for 3, 6, 24 and 48 hr, using 10% of PBS containing 154mM NaCl and 
0.34mM EDTA as vehicle control. The treated cells were harvested for RNA 
isolation and protein extraction. Cytotoxicity based on the dye exclusion method was 
examined after 48 hr incubation. The percentages of cell viability of the cells treated 
with vehicle control and Ox-LDL was 93%and 92%, respectively. 
4.2.6 Statistical Analysis 
 Data analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) version 18.0 for Windows (SPSS UK Ltd, UK).  Determination of 
correlations in gene expression analysis and variables of interest were performed 
using Pearson’s correlation coefficient for normally distributed variables and 
Spearman’s rank correlation coefficient for variables that were non-Gaussian 
(LpPLA2). Significance for these tests was set at P<0.05. For additional analysis 
where BMI was noted as a confounding factor for LpPLA2 levels, a partial 
correlation analysis controlling for BMI was performed. Multiple linear regression 
analysis was used to identify potential predictor of LpPLA2; whilst comparison of 
gene expression in in vitro experiments was tested for by one way ANOVA. 
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4.3 Results 
4.3.1 Circulating metabolic markers and LpPLA2 levels. 
T2DM subjects had significantly higher mean BMI (P<0.001), blood glucose 
(P<0.001), LDL (P<0.01), insulin (P<0.001), Ox-LDL (P<0.05) and endotoxin 
(P<0.001) levels and lower HDL (P<0.001), compared with lean non-diabetic 
subjects. Additionally, the significant difference in mean BMI (P<0.001), blood 
glucose (P<0.001), HDL (P<0.001), insulin (P<0.001) and endotoxin levels 
(P<0.001) were observed when compared with obese, non-diabetic subjects (Table 
4.3.1.1). 
Table 4.3.1.1 Baseline characteristics of non-diabetic and T2DM subjects.  
                                           Non-T2DM   (n=72)   
             Lean   Overweight  Obese  
                                 n=26        n=22         n=24 
 
BMI (Kg/m2) 22.1±0.2     26.9±0.3*       33.7±0.7 ***  44.2±1.8*** †††  
Glucose (mmol/L) 5.0±0.3       4.8±0.08      5.5±0.2       8.7±0.5***††† 
Cholesterol (mmol/L) 4.8±0.2 5.3±0.2 5.7±0.3 * 5.0±0.3   
Triglyceride (mmol/L) 0.9±0.06  1.04±0.12 1.7±0.2 **  1.4±0.2 ** 
LDL (mmol/L) 2.6±0.16  3.04 ±0.2 3.0±0.2 3.5±0.3 ** 
HDL (mmol/L)  1.8±0.08 1.8±0.1 1.6±0.09   1.2±0.1*** †††  
Insulin (µIU/mL) 5.2±0.6  7.14±1.2 11.6±1.6 * 24.9±2.9 ***†††  
Endotoxin (EU/mL) 2.1±0.2 2.8±0.2 2.5±0.3 7.8±0.9*** 
Ox-LDL (U/L) 39.67±1.4  43.01±3.2 49.76±4.7 63.37±6.7 ***  
LpPLA2 (ng/mL) 125.04±8.3 140.62±9.2 138.17±12.4  135.35±10.1*   
Values were presented as mean ± SEM. Unpaired t test analysis was performed 
to identify differences between lean vs overweight, lean vs obese, lean vs 
T2DM (*, P<0.05; **, P<0.01; ***, P<0.001) and obese vs T2DM (†††, 
P<0.001). 
 
T2DM (n=14) 
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4.3.2 Circulating LpPLA2 is associated with metabolic markers and endotoxin. 
 The relationships between LpPLA2 and metabolic markers were determined 
using linear regression analysis. There were significant positive correlations between 
serum LpPLA2 and cholesterol (r=0.618, P<0.001), TG (r=0.442, P<0.001), LDL 
(r=0.580, P<0.001), endotoxin (r=0.334, P<0.001) and Ox-LDL (r=0.365, P<0.001) 
in non-diabetic subjects (Fig 4.3.2.1).  
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Figure 4.3.2.1 Relationships 
between serum LpPLA2 and 
Cholesterol (A), Triglyceride (B), 
LDL (C), Ox-LDL (D) and 
Endotoxin (E), as demonstrated 
by Spearman’s rank correlation 
coefficient with line of best fit.  
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 In addition, there were positive correlations between LpPLA2 and cholesterol 
(r=0.599, P<0.05), LDL (r=0.637, P<0.01) and Ox-LDL (r=0.791, P<0.001) in 
T2DM subjects (Table 4.3.2.1).  
 
Table 4.3.2.1. Correlations between circulating LpPLA2 and metabolic 
markers  
                        non-T2DM   
All            lean      overweight   obese          T2DM  
n=72          n=26           n= 22  n=24         n=14 
BMI (Kg/m2) 0.185 0.187 0.167 0.110 0.137  
Glucose (mmol/L) 0.152 0.302 -0.160 0.316      0.484 
Cholesterol (mmol/L) 0.618*** 0.649** 0.489* 0.881*** 0.599*  
Triglyceride (mmol/L)  0.442*** 0.479* 0.410 0.426 0.209  
LDL (mmol/L)  0.580*** 0.662** 0.349 0.784***     0.637** 
HDL  (mmol/L)  -0.264 -0.321 0.210 -0.651** 0.187 
Insulin (µIU/mL)  0.182 0.214 0.417 0.007 0.088 
Endotoxin (EU/mL) 0.334*** 0.554** 0.156 0.395 0.379 
Ox-LDL (U/L) 0.365*** 0.529** 0.281 -0.100           0.791*** 
Values shown are correlation co-efficient (*,P<0.05; **,P<0.01; *** P<0.001) 
 
 Using partial correlation analysis, and controlling for BMI, positive 
associations between LPPLA2 and cholesterol (r=0.53, P<0.001), LDL (r=0.56, 
P<0.001), and Ox-LDL (r=0.34 P=0.027) remained significant across the combined 
cohort. Again using partial correlation analysis, and controlling for BMI, in subjects 
with T2DM alone showed a similar positive association between LpPLA2 and 
cholesterol (r=0.66, P=0.019), LDL (r=0.738, P=0.006), and Ox-LDL (r=0.75, 
P=0.005). 
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(C)    T2DM ; r = -0.132, P = 0.652 
4.3.3 mRNA level of LpPLA2 and ALOX15  in human adipose tissue. 
 To study the roles of LpPLA2 in adipose tissue inflammation, mRNA level of 
ALOX15 was determined. The results from this study showed that there were no 
significant correlations between LpPLA2 and ALOX15, in either all subjects or those 
split by non T2DM or T2DM status (Fig 4.3.3.1). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3.1. Correlation between LpPLA2 gene expression and ALOX15 gene 
expression for (A) All subjects, (B) Non T2DM subjects and (C) T2DM subjects. 
The line of best fit denoted as r and the corresponding P values are noted in the 
relevant graph. 
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4.3.4 mRNA level of LpPLA2 and COX2 in human adipose tissue. 
 This study showed that there were significant negative correlations between 
LpPLA2 and COX2 (P<0.05) in the T2DM subjects, whilst no significant 
correlations were observed in either the non-T2DM subjects or the whole cohort 
together.      
 
 
 
 
Figure 4.3.4.1. Correlation between LpPLA2 gene expression and COX2 gene 
expression for (A) All subjects, (B) Non T2DM subjects and (C) T2DM subjects. 
The line of best fit denoted as r and the corresponding P values are noted in the 
relevant graph. 
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4.3.5 mRNA level of LpPLA2 and IL-6 in human adipose tissue. 
 This study showed that there were significant negative correlations between 
LpPLA2 and IL-6 (P<0.05) in T2DM subjects whilst this correlation was noted 
observed either in the non-diabetic group or the group as a whole (Figure 4.3.5.1).       
 
 
 
 
 
Figure 4.3.5.1. Correlation between LpPLA2 gene expression and IL-6 gene 
expression for (A) All subjects, (B) Non T2DM subjects and (C) T2DM subjects. 
The line of best fit denoted as r and the corresponding P values are noted in the 
relevant graph.  
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4.3.6 Effects of ox-LDL treatment on PLA2 expression in differentiated human 
adipocyte cell line, chub S7 
 Cells treated with Ox-LDL induced an acute rise in LpPLA2 expression, after 
6 hr treatment and declined up until 24 hr (P<0.001; Fig 4.5.6.1 A). The gene 
expression of cPLA2 and iPLA2 was not modulated under the same stimulatory 
condition.  
 
 
  
Figure. 4.5.6.1. Effects of ox-LDL on (A) LpPLA2 gene, (B) cPLA2 and (C) 
iPLA2 expression. Differentiated Chub-S7 adipocytes were treated with 100 µg/ml 
ox-LDL for 3, 6, 24 and 48 hr. Phosphate buffer saline containing 0.34 mM EDTA 
was used as control. mRNA level of LpPLA2 was measured by real-time RT-PCR. 
The data were normalized to 18S RNA. The fold change in expression was 
calculated relative to control of each time point. Protein level of LpPLA2 was 
measured by ELISA in cell homogenates. The difference of expression were assessed 
by one way ANOVA test (***, P<0.001 vs control) 
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4.3.7 Effects of ox-LDL treatment on IL-6 and COX2 expression in 
differentiated human adipocyte cell line, chub S7 
 IL-6 gene expression was up-regulated within 3 h incubation when treated the 
cell with ox-LDL. However, ox-LDL treatment did not alter COX2 expression.  
 
FIG. 4.5.7.1. Effects of ox-LDL on (A) IL-6 and (B) COX2 gene expression. 
Differentiated Chub-S7 adipocytes were treated with100 µg/ml ox-LDL for 3, 6, 24 
and 48 hr. Phosphate buffer saline containing 0.34 mM EDTA was used as control. 
mRNA level of IL-6 and COX2 was measured by real-time RT-PCR. The data were 
normalized to 18S RNA. The fold change in expression was calculated relative to 
control of each time point. The difference of expression were assessed by one way 
ANOVA test (P<0.001 vs control) 
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4.4 Discussion 
In this study, it was observed that LpPLA2 correlated with specific 
cardiometabolic risk factors such as LDL-cholesterol, HDL-cholesterol, ox-LDL 
cholesterol, as well as a relative new biomarker of metabolic risk, endotoxin. Whilst 
such associations identified are not necessarily causal they do highlight the relevance 
of LpPLA2 as a potential new biomarker of cardiometabolic risk as other studies 
suggest (A. Cai et al., 2013; Gu et al., 2014; Hong et al., 2013; S. B. Li et al., 2013; 
Mangili et al., 2014). Furthermore examining subjects across adiposities and those 
with T2DM indicated that T2DM subjects develop a more pronounced metabolic 
dysfunction than obesity per se. This aspect appears relevant as a raised LpPLA2 
level was noted in such T2DM subjects. Whilst the current in vitro adipocyte studies 
identified that oxidation of LDL was accompanied by an increase in LpPLA2 mRNA 
expression in a similar manner to prior studies in macrophages (Markakis et al., 
2010; W.-Y. Wang et al., 2010). 
Yet interestingly when examining the cohorts in more detail, considering the 
potential influence of adiposity, it was identified that controlling for BMI did not 
affect the positive correlation of circulating LpPLA2 with cholesterol, LDL or Ox-
LDL across the combined cohort, or within the T2DM cohort. The correlation 
between lipids and LpPLA2 affirms previous studies and highlights how the relative 
distribution of LDL and HDL may impact on LpPLA2’s function to either being 
atherogenic or atheroprotective, impacted by diabetic status and glycaemic control 
(Sanchez-Quesada et al., 2012).  
Beyond the cardiometabolic parameters the positive correlation observed 
between endotoxin and LpPLA2 represents a novel insight into the effect of 
endotoxin on another inflammatory mechanism, in addition to the innate immune 
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cascade (Al-Attas et al., 2009; Baker et al., 2009; Creely et al., 2007). Previous 
studies have shown that endotoxin, as well as saturated fatty acids, may up-regulate 
the innate immune cascade, with activation of nuclear factor kappa B (NFκB) leading 
to down-stream activation of numerous pro-inflammatory factors (Creely et al., 
2007; Youssef-Elabd et al., 2012). Interestingly, previous studies in endothelial cells 
and macrophages have also shown that the LpPLA2 signalling pathway is regulated, 
in part, by NFB, which would also align with the mechanism through which 
endotoxin, as well as lipid mediators, influence circulating LpPLA2 (Baker et al., 
2009; Creely et al., 2007; Senokuchi et al., 2005; Sonoki et al., 2008; Youssef-Elabd 
et al., 2012). This may therefore explain why endotoxin appears positively correlated 
with serum LpLA2.   
The positive correlation between circulating LpPLA2 and ox-LDL were also 
observed in this study. Ox-LDL is widely considered as an important risk factor for  
cardiovascular diseases which recently, has been reported to augment the 
cardiovascular disease risk prediction within the Framingham model (Gómez et al., 
2014). Similar to endotoxin, ox-LDL has also previously been reported as a regulator 
of LpPLA2 expression in monocyte and endothelial cells via p38 /NFB pathway. In 
addition, LpPLA2 has been demonstrated to hydrolyze oxidized phospholipid in 
LDL particles, resulting in reduction of atherogenic effect of ox-LDL on foam cell 
formation. However during this process, lysophospholipid and oxidized free fatty 
acid are also gradually generated, leading to further increase oxidative progression 
and inflammation activation. 
Since LpPLA2 plays this bi-functional enzyme role, the correlation between 
adipose tissue LpPLA2 mRNA expression and other inflammatory markers, such as 
ALOX15, COX2 and IL6 were studied to understand whether an ex vivo tissue 
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mRNA analysis of inflammatory markers may correlate with changes in LpPLA2 
due to the known interactions through NFB in adipose tissue (Baker et al., 2009; 
Harte et al., 2013b; McGee et al., 2011). However ex vivo mRNA analysis in adipose 
tissue taken from non T2DM subjects did not identify any correlations between 
LpPLA2 versus, IL-6, COX2 or ALOX15. Whilst sub-cohort analysis showed a 
negative correlation between LpPLA2 with COX2 and IL-6, in adipose tissue taken 
from T2DM subjects. This may indicate that in a pathological state such as T2DM, 
high expression of LpPLA2 in adipose tissue may not additionally promote 
inflammation but likely resolve inflammation in T2DM. However the reduction in 
mRNA of IL-6 and Cox2 may have arisen due to the influence of medications that 
the T2DM patients were on. Since previous research has shown that statins can 
reduce IL-6 and Cox2 expression directly from human adipose tissue, macrophages 
and endothelial cells (Baker et al., 2006; Q. Li et al., 2006; Massaro et al., 2010), 
whilst the effect of statins on LpPLA2 mRNA expression in adipose tissue has not 
been previously studied.   
Due to the potential influencing effects of diabetes medication on 
inflammatory markers and LpPLA2 an in vitro study was undertaken to understand 
the impact of ox-LDL in an adipocyte culture system. Human differentiated 
adipocyte Chub S7 cells (Darimont et al., 2003) were treated with ox-LDL and gene 
expression changes measured over time.  
From these studies it was identified for the first time that ox-LDL induced 
LpPLA2 expression in adipocyte after 6 h incubation and slowly returned into basal 
level within 24 h, whereas IL-6 mRNA levels were up-regulated within 3 h of 
incubation and declined within 6 h. Whereas ox-LDL treatment did not appear to 
alter either cPLA2 or iPLA2 expression. The expression of the two isoforms, cPLA2 
  
95 
 
and iPLA2 were determined as it has been previously reported that cPLA2 activity is 
activated by ox-LDL treatment, promoting inflammation in both mouse monocyte 
(W.-Y. Wang et al., 2010) and fibroblast (Lupo et al., 2007) cell lines. Thus, it was 
necessary to determine within in a human adipocyte system, if activation of cPLA2 
and iPLA2 may account for the potential inflammation, which at least in these 
adipocyte cultures did not appear to be the case.   
 Also in this current study it appeared COX2 mRNA expression did not alter 
when treated with ox-LDL in adipocyte, suggesting that there were no direct 
association between activation of LpPLA2 by ox-LDL and COX2 in differentiated 
human adipocyte. COX2 was utilised as a candidate to increase in this culture system 
as prior studies with primary vascular smooth muscle cells taken from T2DM 
subjects had shown that COX2 protein expression increased in response to TG 
(Gordillo-Moscoso et al., 2013). However the change in culture system, metabolic 
state as well as differences in Cox2 in ex vivo adipose tissue from different metabolic 
states appear to impact on COX2 regulation and may therefore suggest its regulation 
is more complicated than first considered. 
Taken together, the current in vitro data  suggest that ox-LDL can up regulate 
both LpPLA2 and IL-6 in adipocytes whilst the ex vivo AT data was unable to 
confirm this in T2DM subjects probably due to interference through medicinal 
treatment. However LpPLA2 mRNA expression appears regulated by ox-LDL 
treatment in the Chub-S7 AbdSc cell line and these findings align with previous data 
which noted that LP-LA2 protein expression is higher in AbdSc AT compared to Om 
AT across all groups (noting that the differences in adipose tissue depot protein 
expression may influence cell responsiveness to ox-LDL).  
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In summary, these studies affirm and extend our current knowledge on 
circulating LpPLA2 and its association lipid profiles including ox-LDL and extend 
this through data on endotoxin. Furthermore linear regression analysis identified that 
ox-LDL was a significant predictor of circulating LpPLA2 which was confirmed by 
in vitro studies showing the regulatory effects of ox-LDL on Lp-PLA2 expression. 
However further studies are required to ascertain a direct cause and effect 
relationship between ox-LDL and LpPLA2. Furthermore as lysophospholipid and 
oxidized free fatty acid are products of LpPLA2 activity, high expression of LpPLA2 
in adipocytes might be represent an important source of circulating ox-LDL in 
obese/T2DM subjects. As such further studies assessing the inhibition of LpPLA2 
activity appear important to investigate its effect on LDL oxidation and LpPLA2 
functional influence in increasing metabolic disease risk. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER 5 : The in vitro Role of LpPLA2 in the 
Conversion of LDL into the Atherogenic ox-LDL in Human 
Adipocytes. 
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5.1 Introduction 
 Lipoprotein-associated phospholipase A2 (LpPLA2) is an enzyme that can 
hydrolyse polar phospholipids, such as those generated during the oxidation of low 
density lipoprotein (Ox-LDL), which results in the production of pro-inflammatory 
mediators, such as lysophosphatidylcholine and oxidised fatty acids(Rosenson & 
Stafforini, 2012). Recent interest in LpPLA2 has arisen due to a number of 
epidemiological studies that have shown circulating LpPLA2 to be up-regulated in 
conditions of inflammation and cardiovascular disease (CVD) (Khakpour & 
Frishman, 2009; Kinney et al., 2011; Oei et al., 2005; Winkler et al., 2007). Whilst 
limited studies, to date, have examined circulating LpPLA2 in patients with T2DM, 
studies have highlighted that LpPLA2 levels are positively correlated with body mass 
index (BMI), as well as triglycerides (TG), low density lipoprotein (LDL) and high 
density lipoprotein (HDL) and ox-LDL. Furthermore, elevated LpPLA2 levels have 
been associated with predicting T2DM (Maria Waegner et al., 2011; Nelson et al., 
2012), although other reports have not been conclusive (Constantinides et al., 2011; 
Nelson et al., 2011). Much of the research, to date, has centred on CVD and the role 
of the macrophage as a major source of LpPLA2, although other cells types are also 
noted to express LpPLA2 including T lymphocytes, mast cells and hepatocytes (W.-
Y. Wang et al., 2010; M. Yang et al., 2010; Zalewski et al., 2006).  
In particular oxidative modification of LDL (oxLDL) is regularly associated 
with hypercholesterolemia and coronary artery disease. Furthermore despite the 
initial step of form cell formation in clearly understood which causes the 
atherosclerotic lesion to develop, the mechanisms underlying oxidative modification 
of LDL remains unclear (Vickers et al., 2009; W.-Y. Wang et al., 2010; M. Yang et 
al., 2010). However despite this, recent work has sought to understand the role of 
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LpPLA2 and its role in etiology on plaque formation through oxidative modification 
of LDL. These previous in vitro studies, using monocytes, have specifically 
examined the stimulatory effect of Ox-LDL on LpPLA2 activity, which indicates the 
potential influence of LpPLA2 on arterial inflammation (W.-Y. Wang et al., 2010); 
whilst in vivo studies have shown that Ox-LDL are significantly associated LpPLA2 
in carotid endarterectomy (CEA) tissues (Vickers et al., 2009). 
Other studies also highlight that elevated LpPLA2 activity promotes the 
development of vulnerable atherosclerotic plaques, and elevated plasma levels of this 
enzyme are associated with an increased risk of coronary events. Whilst a new 
selective oral inhibitor of lipoprotein-associated phospholipase A2 known as 
Darapladib has been shown to reduce instability in plaques and reduce coronary 
events (Dave et al., 2014; Johnson et al., 2014; White et al., 2014). This inhibitor 
may also reduce the LpPLA2 enzymatic activity critical for eliciting macrophage 
responses associated with a variety of inflammatory processes and signaling 
pathways such as c-Jun-kinase (JNK) (Tzang et al., 2009). 
However to date whilst it is understood that ox-LDL increases with obesity 
and that LpPLA2 can induce inflammation in macrophages no comparable study has 
been undertaken to examine LpPLA2 in human adipocytes; despite the knowledge 
that adipocytes possess many immune like cell characteristics. As such these current 
sought to determine whether the adipocyte can convert LDL to ox-LDL in cultured 
human adipocytes. 
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5.2 Methods and Materials 
5.2.1 Cell cultures and human lipoprotein treatment 
 The AbdSc pre-adipocytes Chub S7 cells were grown in 6-well plates to 
confluence in phenol red-free Dulbecco’s modified Eagle’s medium (PRF-DMEM F-
12) containing 10% bovine serum, penicillin (100 U/ml), streptomycin (100 μg/ml) 
and transferrin (5 μg/ml) at 370C, 5%CO2 incubation until confluent. To undertake 
cell differentiation, AbdSc pre-adipocytes were maintained in promocell pre-
adipocyte differentiation media (PromoCell, Germany) for 48 hr and, following this 
time period, the cells were maintained in the promocell adipocyte nutrition media 
(PromoCell, Germany) for fourteen days, with media changes every two days. 
Following the differentiation period the AbdSc differentiation adipocytes were given 
a 24 hour wash out period in PRF-DMEM/F12. To study the effect of LDL and Ox-
LDL on LpPLA2 expression, a human AbdSc pre-adipocyte Chub S7 cell line was 
utilized, which originated from a female subject (Darimont et al., 2003). Chub S7 
cells were maintained in growth media and differentiated under the same conditions 
as the human primary AbdSc pre-adipocyte cells, described above.  
 The differentiated AbdSc Chub S7 cells were treated with either LDL (200 
µg/mL) or Ox-LDL (100 µg/mL; Kalen Biomedical, USA) for 3, 6, 24 and 48 hr, 
using 10% of PBS containing 154mM NaCl and 0.34mM EDTA as vehicle control. 
The treated differentiated AbdSc Chub S7cells were harvested for RNA isolation and 
protein extraction.  
The differentiated AbdSc Chub S7 cells were also cultured with and without 
20µM Darapladip, the LpPLA2 inhibitor in conjunction with Ox-LDL (100 µg/mL; 
Kalen Biomedical, USA) for 3, 6, 24 and 48 hr, using 10% of PBS containing 
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154mM NaCl and 0.34mM EDTA as vehicle control. The treated differentiated 
AbdSc Chub S7cells were harvested for protein extraction as detailed in Chapter 2. 
5.2.3 Cellular Protein concentration 
 Human AbdSc Chub S7 cells following treatment were harvested and 
resuspended in Phosphosafe™ Extraction buffer (Novogen®, Merck, Germany). 
Protein concentrations
 
were determined using the Bio-Rad Detergent Compatible 
protein
 
assay kit (Bio-Rad Laboratories, CA) (Bradford, 1976) and quantified using 
the nanospectrophotometer (GeneFlow, UK). 
5.2.3 Cell viability in the in vitro cultured Chub S7 cells 
 The viability of adipocytes was assessed using the trypan blue dye exclusion 
method and examined at 48hr following initial treatment. The percentages of cell 
viability of the cells treated with vehicle control, LDL and Ox-LDL was 93%, 97% 
and 92%, respectively. 
5.2.4 Assessment of Ox-LDL and LpPLA2 in cultured cells 
 Ox-LDL and LpPLA2 were measured using commercially available solid 
phase enzyme-linked immunosorbant assay (ELISA; Mercodia Oxidized LDL 
ELISA, Sweden; intra-assay percentage coefficient of variation %CV = 6.4; inter 
assay % CV = 7.4) and R&D system Human PLA2G7/PAF-AH/LpPLA2 
(Quantikine ELISA, UK; intra-assay %CV = 6.8, inter-assay %CV = 9.6). 
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5.2.5 Statistical Analysis 
 Data analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) version 18.0 for Windows (SPSS UK Ltd, UK).  Analysis of 
variance (ANOVA) was used to compare the effects of oxidized LDL on LDL and 
LpPLA2 expression across various time points. ANOVA with Bonferroni correction 
was undertaken in SPSS with automatic adjustment to the detailed significance 
dependent upon the number of comparisons.  
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5.3 Results 
5.3.1 The in vitro effect of Ox-LDL on LpPLA2 expression in human adipocyte 
cell line, Chubs S7 
 Cells treated with Ox-LDL induced an acute rise in LpPLA2 mRNA, post 3 
hr treatment, that slowly declined up until 24 hr as previously showed in Chapter 4 
(P<0.001; Figure 5.3.1 A). LpPLA2 protein expression was significantly higher 
compared with control by 3 hr. The protein level gradually decreased after 6 h 
incubation (P<0.001; Figure 5.3.1 B).  
 
 
Figure 5.3.1 ox-LDL induced LpPLA2 expression. Differentiated Chub S7 
adipocytes were treated with 100 µg/ml oxidized LDL for 3, 6, 24 and 48 hr. 
Phosphate buffer saline containing 0.34 mM EDTA was used as control. The 
intracellular protein level of LpPLA2 was measured by ELISA. The data were 
normalized to total protein. The difference in expression was assessed by two way 
ANOVA test (***, P<0.001, each time point vs. control; , P<0.001, each time 
vs. 3hr) 
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5.3.2 Activation of LpPLA2 by LDL in human adipocyte cell line, Chubs S7. 
 Reduction of LpPLA2 mRNA level was observed after treated the cells with 
LDL. After 48 hr incubation, the mRNA level significantly increased compared to 
control as previously showed in Chapter 4 (P<0.001; Figure 5.3.2 A). LpPLA2 
protein level gradually decreased after 3 hr incubation (P<0.001) and then 
significantly increased at 48 hr incubation compared to 24 hr incubation (P<0.001; 
Figure 5.3.2 B) 
 
 
 
Figure 5.3.2 LDL induced LpPLA2 expression Differentiated Chub S7 adipocytes 
were treated with 200 µg/ml LDL for 3, 6, 24 and 48 hr. Phosphate buffer saline 
containing 0.34 mM EDTA was used as control. The intracellular protein level of 
LpPLA2 was measured by ELISA. The data were normalized to total protein The 
difference in expression was assessed by two way ANOVA test (*, P<0.05; ***, 
P<0.001, each time point vs. null; , P<0.001, 48hr vs. 24 hr incubation 
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5.3.3 Oxidation of LDL by adipocytes was mediated by LpPLA2 
Further analysis of LDL treatment determined whether the adipocyte cells 
were converting the LDL into Ox-LDL. The percentage of Ox-LDL in LDL treated 
media was determined, as shown in Figure 5.3.3. At 48 hr incubation, the Ox-LDL 
level had increased by 21.5% compared with the treatment media at 3 hr incubation 
(P<0.05).  
 
Figure 5.3.3 Increased ox-LDL in LDL treatment in human adipocyte cell line. 
Differentiated Chub S7 adipocytes were treated with 200 µg/ml LDL for 3, 6, 24 and 
48 hr. Phosphate buffer saline containing 0.34 mM EDTA was used as control and 
Ox-LDL was measured by ELISA in conditioned media. Ox-LDL level at 3 hr was 
calculated as 100% ox-LDL in condition media. The change in % ox-LDL over time 
was assessed by two way ANOVA test with , P<0.05, 48 hr vs. 3 hr incubation. 
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5.3.4 Changes in ox-LDL production by the use of an LpPLA2 inhibitor. 
 To confirm the ability of adipocyte in LDL modification via LpPLA2, the 
cells were treated with LDL plus a LpPLA2 inhibitor, darapladib. The ox-LDL level 
in conditioned media was approximately 19.8% lower in the cells treated with LDL 
plus darapladib after 72 incubation compared to the cells treated with LDL alone 
(P<0.05; Figure 5.3.4) 
 
 
 
 
 
 
 
Figure 5.3.3 LpPLA2 inhibitor, darapladip, reduced ox-LDL production in 
vitro. Differentiated Chub S7 adipocytes were treated with 200 µg/ml LDL with or 
without 20 µM darapladib (SB) for 3, 6, 24 and 48 hr. Phosphate buffer saline 
containing 0.34 mM EDTA was used as control and Ox-LDL was measured by 
ELISA in conditioned media. The change in % ox-LDL over time was assessed by 
two way ANOVA test with , P<0.05, 48 hr vs. 3 hr incubation. 
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5.4 Discussion 
This present study is the first study to show that LpPLA2 within the 
adipocyte appears to regulate the production of ox-LDL suggesting that the adipocyte 
could act as another substantial source of ox-LDL production and may explain why 
increasing adiposity could contribute to rising ox-LDL levels. Furthermore the use of 
an LpPLA2 inhibitor provided further evidence that the production of Ox-LDL was 
regulated by LpPLA2 expression in the adipocyte. This work has important 
ramifications for highlighting that adipose tissue may act as separate and significant 
source of Ox-LDL production apart from foam cells within unstable atherogenic 
plaques noted in CAD (Dave et al., 2014; Johnson et al., 2014).  
Due to the dynamic nature of LpPLA2 in vitro studies also observed that both 
Ox-LDL and LDL could induce LpPLA2 expression in human adipocyte. Ox-LDL 
treated cells acutely increased the new synthesis of LpPLA2 as observed by 
increasing mRNA expression noted as early as 6 hr post-incubation. Interestingly 
LpPLA2 protein level appeared to be induced at an even early time point, as early as 
3 hr post-incubation. As such the raised LpPLA2 protein expression did not appear to 
be associated with mRNA production within the adipocyte. One rationale for this 
apparent inconsistency may arise due to the capability of the adipocyte to engulf Ox-
LDL and LDL particles into the cell. This function has an important impact on 
LpPLA2, as following Ox-LDL uptake the adipocyte can digest the ox-LDL particle 
to release fatty acid, cholesterol as well as LpPLA2. Thus, the higher protein 
expression compared with the control observed at 3h post-incubation may appear to 
reflect the exogenous LpPLA2 available, whilst the higher mRNA expression 
observed at 6 hr post-incubation represents the newly synthesised LpPLA2 gene 
expression. The increased mRNA expression level resulted in LpPLA2 protein 
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expression to remain high inside the adipocyte at the 6 hr post-incubation time point. 
A similar phenomenon was also observed in the adipocytes treated with LDL where 
the LpPLA2 protein expression was higher than control 3 hr post-incubation and then 
gradually reduced over the 24 hr period. Unlike oxLDL treatment, the LpPLA2 
mRNA level in the adipocyte treated with LDL showed a significant reduction in 
expression at 6 hr post-incubation, leading to a steady decline in LpPLA2 protein 
expression over time. Although, interestingly there was a subsequent up regulation of 
LpPLA2 mRNA and protein expression in LDL treated cells at 48 hr post-incubation. 
It appears that a couple of possible scenarios which occur in vivo could explain why 
such LDL modification may occur in in vitro. 
 It is clear that Ox-LDL is regularly associated with obesity induced 
hypercholesterolemia and CAD, with Ox-LDL known to promote foam cell 
formation, leading to causing the atherosclerotic lesion (Johnson et al., 2014). The 
mechanism underlying the in vivo oxidative modification of LDL remains unclear. 
However LDL is highly oxidized by metal ions such as Fe
2+
 and Cu
2+ 
as well as 
superoxide (O
.-
) by Fenton reaction (Kappus, H. 1985) 
    
 
 
As such in vitro studies of smooth muscle cells (Heinecke, J 1984, Heinecke, J 
1986), monocyte (Hiramatsu, K, 1986), macrophage (Wilkins, G, 1990) and 
endothelial cell (Steinbrecher, U.P., 1988) has established that there is a postulated 
release of superoxide which is considered to promote LDL modification. However, 
under physiological condition, oxidative stress induced by superoxide is controlled 
by the anti-oxidative system such as superoxide dismutase, NADH and glutathione 
O2
.-
    +    Me
(n+1)+
                       O2   +   Me
n+
                                      (1) 
H2O2   +   H
+
   +   Me
n+
                     HO
.
   +   H2O   +   Me
(n+1)+
         (2) 
  
109 
 
and superoxide itself has low reactivity to LDL (Bedwell, S., 1989). Additionally, in 
vivo studies have highlighted that the accumulation of cu
2+
 and Fe
2+
 has been 
observed in artery walls taken from atherosclerotic lesion, which may impact on 
LDL modification (Dubick, M., 1987, Smith, C. 1992); particularly as iron 
overloaded in thalassemia patients has been associated with a high risk of 
cardiovascular disease. Since, superoxide has less capacity in oxidation under 
physiological pH and iron and copper overloaded diseases are quite rare.  However 
other mechanisms may also lead to LDL modification there through the 
dysregulation of pro- and anti-inflammatory mediators which can play role a role in 
the pathogenesis of cardiovascular disease as well. As mentioned in previous chapter, 
LpPLA2 is the bi-functional enzyme, containing both pro- and anti-inflammatory 
properties which depend on physiological and pathological state. In addition, 
previous studies have shown the up regulation of LpPLA2 in adipocyte taken from 
obese T2DM subjects and positive correlations between LpPLA2 and ox-LDL 
(Maria Waegner et al., 2011; Nelson et al., 2011). 
As the early and late up-regulation of LpPLA2 up-regulation was observed in 
adipocyte treated with Ox-LDL and LDL, studies were undertaken to assess whether 
LpPLA2 may be interconverting LDL and Ox-LDL due to the relative changes over 
time as the adipocytes are held within a closed system. As such an LpPLA2 inhibitor, 
darapladib, was utilised to ascertain whether the relative changes in Ox-LDL 
production were directly related to LpPLA2 activation. The LpPLA2 inhibitor 
studies co-treating cells with LDL identified that that the production of resulting ox-
LDL was significantly decreased with the inhibitor. Further due to LpPLA2s bi-
directional nature of LpPLA2 in the adipocyte this may also help to explain why in 
such a closed system as LDL levels reduced and Ox-LDL increased, LpPLA2 
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expression may have altered. Such in vitro findings also indicate that LpPLA2 
expression may have a significant impact on modifying in vivo systemic LDL. 
Therefore with increasing adiposity and rising LDL levels in patients with obesity 
and T2DM this leads to increased production of Ox-LDL without the necessarily 
further interconversion of Ox-LDL as noted in vitro as Ox-LDL can move away from 
the adipose tissue through the circulation. In conclusion these current in vitro studies 
highlight the functional capability of LpPLA2 within the human adipocyte and 
another key site of Ox-LDL production with implications for increased disease risk 
in patients with obesity.   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CHAPTER 6 : Reduction of TLR4 Expression 
in Adipose Tissue after Bariatric Surgery in T2DM. 
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6.1 Introduction 
 Adipose tissue (AT) is an endocrine organ, releasing both pro-inflammatory 
cytokines (e.g. TNF, IL-6, IL-1 and MCP-1) and anti-inflammatory cytokines 
(e.g. adiponectin, leptin, IL-1R and IL-10) (Giamila, 2005). There are much evidence 
supports that the imbalanced secretion of those adipokines contributes to low grade 
inflammatory diseases such as T2DM and cardiovascular diseases. In human adipose 
tissue, TNF expression correlates with BMI, percentage of body fat and 
hyperinsulinemia, whereas weight loss decreases TNF expression (G. Fisher et al., 
2011). Similarly, increased circulating IL-6 level has been observed in obese and 
insulin resistant subjects (Roytblat et al., 2000; Vozarova et al., 2001). Moreover, 
TNF and IL-6 have long-term effects in IRS-1, GLUT4 and PPAR gene 
suppression in 3T3 adipocytes, resulting in insulin resistance (Rotter, Nagaev, & 
Smith, 2003). In contrast adiponectin is widely known as the insulin-sensitizing 
adipokine with the capacity to suppress TNF expression and induce IL-10 and IL-
1Ra expression. Decreased circulating adiponectin concentration has been negatively 
associated with insulin resistance and T2DM. Whilst the molecular mechanisms of 
how the activation and changes in inflammation in AT remains unclear. It is apparent 
that increasing fat mass which expands fat droplets, reduced angiogenesis, increased 
cellular hypoxia, and innate immune activation may all contribute to inflammation in 
the obese AT state. In such cases the cellular response appears to mainly activate the 
IKK/NFB and JNK pathway, consequently activating the production of chemokines 
and pro-inflammatory cytokines (J. Ye, 2009; Jianping Ye, 2011). Previous data in 
human adipose tissue affirms the up regulation of NFB and JNK in obese state 
(Harte et al., 2013a). Studies have also sought to elucidate other systemic factors that 
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may mediate the inflammatory state in obesity. Studies have shown that free fatty 
acids are raised in obesity (Horowitz et al., 1999; Horowitz & Klein, 2000), with free 
fatty acids reported to induce NFB activity via activated of the key innate immune 
receptors, the toll like receptors (TLRs) (Youssef-Elabd et al., 2012) and reduce 
glucose uptake in muscle cells (Hommelberg, Plat, Langen, Schols, & Mensink, 
2009). Adiponectin also appears to regulate inflammation through TLRs and NFB 
and peroxisome proliferator-activated receptor gamma 2 (PPAR2) (Huang, Park, 
McMullen, & Nagy, 2008; Yamaguchi et al., 2005; Yessoufou et al., 2009).  
Whilst obesity provides a state of chronic inflammation bariatric surgery 
provides an effective therapy for morbid obesity with T2DM to reduce the insulin 
resistant state and improve other co-morbidities associated with obesity such as 
hyperlipedemia, hypertension and obstructive sleep apnea (Bae, Lee, Yun, & Heo, 
2014; Nienhuijs, de Zoete, Berende, de Hingh, & Smulders, 2010; Svane & 
Madsbad, 2014). A recent systemic bariatric surgery review which examined 136 
studies with a total of 22094 patients (Buchwald et al., 2011) identified that 61.23% 
of patients reported weight loss, whilst 76.8% completely resolved their diabetes 
status. Furthermore the metabolic improvements such as resolving diabetic status 
were also coupled with reduction in serum triglyceride, VLDL and free fatty acids 
without significant weight loss post surgery (Curry et al., 2011; Magkos et al., 2010). 
However interestingly, no study to date has examined the potential impact of 
metabolic parameters on AT metabolism and the influence of weight loss to resolve 
the AT inflammation Therefore for this study, the inflammatory related gene 
expressions in AT were examined pre and 6 months post-bariatric surgical 
intervention and its relationship with metabolic changes due to surgery, particularly 
understanding the influence of in vivo and in vitro triglycerides on AT inflammation.  
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6.2 Materials and methods 
6.2.1 Subjects: Serum and tissue collection 
For this study, women were recruited with morbid obesity and T2DM and 
under-went bariatric surgery (n= 30). All subjects had their height, weight and BMI 
measurements taken using standard equipment. Detailed medical drug histories were 
taken and those subjects on medication considered to alter inflammatory status were 
excluded, including the thiazolidinediones. Ethical approval was obtained from the 
local research ethics committee and all patients gave written consent.  
Subcutaneous abdominal adipose tissue samples and fasted blood samples 
before and 6 months post-surgery were obtained by needle biopsy. Serum levels were 
analysed as detailed below.  
6.2.2 Surgical procedure 
 The bariatric surgery can be classified into two major techniques. One is 
related to restrictive techniques which reduce the stomach size in order to reduce 
food digestion e.g. adjustable gastric bands and sleeve gastractomy (SG). The 
another surgical techniques is related to a malabsorptive type surgery which reduces 
food intake and absorption by cutting off some part of stomach and pancreas and 
creating bypass between stomach and intestine e.g. biliopancreatic diversion (BPD) 
and the roux-en-Y gastric bypass. In this study, patients were operated by gastric 
banding (n=8), Sleeve gastrectomy (n=14) and Biliopancreatic diversion (n= 8). 
Clinical characteristic of participants are detailed in Table 6.3.1.1. Twenty five of 30 
received metformin, six received sulfonylurea and one received insulin no effect of 
medication was noted in this study on the factors examined.  
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6.2.3 In vivo assessment of the biochemical profile 
 Fasting blood samples were collected from participating subjects and lipid 
profiles and fasting plasma glucose were determined using routine laboratory 
methods, as detailed in Chapter 2. In brief, the routine blood tests included glucose 
and a full cholesterol profile (TGs, HDL and LDL), as noted in Table 1. Insulin 
measurements were performed by a solid-phase enzyme amplified sensitivity 
multiplex immunoassay (Millipore, U.K.), and glucose was measured by a glucose 
oxidase method (YSL 200 STAT plus).  
6.2.4 Protein determination and Western blot analysis 
Human AT was homogenized and resuspended in Phosphosafe™ Extraction 
buffer (Novogen®, Merck, Germany). Protein concentrations
 
were determined using 
the Bio-Rad Detergent Compatible protein
 
assay kit (Bio-Rad Laboratories, CA) and 
quantified using the nanospectrophotometer (GeneFlow, UK). Western
 
blot analysis 
was performed using a method previously described. For Western blotting, in brief, 
40µg of protein samples were loaded onto a denaturing polyacrylamide gel 
(GeneFlow, UK). Protein expression of phosphorylated NFκB (1:1000, Cell 
Signaling, Denvers, MA) and TRAF6 (1:500, Sigma, UK) was assessed using rabbit 
monoclonal antibodies. Equal protein loading was confirmed by
 examining β actin 
protein expression. No statistical difference was observed in
 β actin expression for all 
samples analyzed. A chemiluminescent detection
 
system, ECL/ECL
+
 (GE 
Healthcare, UK), enabled visualization of bands, whereas intensity was determined
 
using densitometry (Genesnap, Syngene, UK). 
  
116 
 
6.2.5 RNA extraction and quantitative RT-PCR 
RNA was extracted from samples using RNeasy lipid tissue kit (Qiagen, UK) 
according to the manufacturer’s instructions. Extraction was followed by a DNase 
digestion step to remove any contaminating genomic DNA. RNA was quantitated 
using the Nanodrop ND-1000 Spectrophotometer (LabTech, UK) and 200ng of RNA 
from each sample was reverse transcribed using Bioscript Reverse Transcriptase 
(Bioline, UK) and random hexamers, according to the manufacturer’s instructions. 
Quantitative real-time PCR was performed with pre-designed gene specific Taqman 
probes and primers (Applied Biosystems, UK, TLR4; Hs00152939_m1, TLR2; 
Hs00610100_m1, IL-6; Hs01075666_m1 and Adiponectin; Hs01004530_m1) in a 
reaction mix containing TaqMan universal PCR master mix (Applied Biosystems, 
UK). All reactions were multiplexed with the housekeeping gene 18S, provided as a 
pre-optimised control probe (Applied Biosystems, UK) enabling data to be expressed 
as delta threshold cycle (ΔCt) values (where ΔCt = Ct of 18S subtracted from Ct of 
gene of interest). Measurements were carried out in triplicate for each sample.  
6.2.6 Statistical Analysis 
 Data analysis was performed using the Statistical Package for the Social 
Sciences (SPSS) version 18.0 for Windows (SPSS UK Ltd, UK).  Student paired t-
test was performed comparing mRNA and protein expression level pre- and post-
surgery (6 months). Analysis of variance (ANOVA) was undertaken with bonferroni 
correction controlling for type 1 error which was used to compare mRNA and protein 
expression among groups with surgery type (adjusted P-value < 0.017, considered as 
statistically significant). ANOVA with bonferroni correction was undertaken in 
SPSS with automatic adjustment to the detailed significance dependent upon the 
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number of comparisons. Determination of correlations in gene expression analysis 
and variables of interest were performed using Pearson’s correlation coefficient for 
normally distributed variables and Spearman’s rank correlation coefficient for 
variables that were non-Gaussian. Significance for these tests was set at P<0.05. 
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6.3 Results 
6.3.1 Characteristics of T2DM subjects pre- and post-bariatric surgery.  
 It was observed that post surgery individual BMI (P<0.001), blood glucose 
(P<0.001), insulin (P<0.001), HOMA-IR (P<0.001), TG (P<0.05), Cholesterol 
(P<0.001) and LDL-cholesterol (P<0.05) were significantly improved (Table 
6.3.1.1). According to individual surgery types, BMI reduction was 11.36% (4.63-
18.55 %) for gastric banding, 10.76% (4.28-16.49%) for SG, 16.96% (14.41-19.09%) 
for BPD and 12.37% (4.68-19.09%) for overall. There was no significant difference 
in percent reduction of blood metabolic markers between gastric banding, SG and 
BPD as noted in Table 6.3.1.2. Bariatric surgery type had no selective effect on 
metabolic improvement following surgery. 
. 
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 Table 6.3.1.1. Patients demographics and biochemical data pre- and post-surgery.          
              ALL (n=30)  Gastric banding (n=8)                     SG (n=14)                       BPD (n=8)  
     Pre  Post  Pre  Post  Pre  Post  Pre  Post  
  Age     54.60±6.64     -  55.88±9.99   -  55.14±5.79    -  52.38±3.5             - 
  Days between pre-    170.0±23.8     -  163.75±21.34   -  183.57±17.84    -  152.50±23.15       - 
  and post- surgery        
  BMI (Kg/m2)   41.26±5.66 36.05±5.16 42.26±7.54 36.83±8.20 40.03±5.46 36.65±4.36 43.30±2.56 35.29±2.60 
 Fasting blood Glucose (mmol/L) 9.35±2.54 7.27±1.68 9.88±2.77 7.28±1.72 9.09±2.19 7.29±1.69 9.28±3.09 7.23±1.83  
Insulin    28.52±19.15 16.29±9.25 25.50±7.33 16.21±6.12 26.40±20.47 16.29±11.34 35.26±24.80 16.39±8.78  
 HOMA IR    11.93±8.92 5.13±3.01 11.26±4.67 5.55±3.05 11.12±9.64 5.06±3.23 14.01±11.34 4.82±2.92 
 Triglyceride (mmol/L)  1.90±1.11 1.46±0.68 1.85±0.73 1.26±0.49 2.10±0.51 1.45±0.73 1.60±0.77 1.67±0.75 
 Total cholesterol (mmol/L)  5.0±0.90  4.45±0.93 4.89±0.93 4.41±0.70 4.98±0.75 4.83±0.84 5.15±1.20 3.84±1.03 
 LDL cholesterol (mmol/L)  3.04±0.90 2.74±0.78 2.96±0.79 2.73±0.65 2.85±0.74 2.98±0.82 3.41±1.21 2.31±0.76  
 HDL cholesterol (mmol/L)  1.09±0.31 1.04±0.32 1.07±0.30 1.10±0.29 1.14±0.35 1.17±0.32 1.00±0.24 0.76±0.13 
 HDL/LDL  ratio   0.39±0.16 0.41±0.16 0.38±0.13 0.43±0.16 0.43±0.19 0.43±0.18 0.33±0.15 0.36±0.12 
 TG/HDL ratio   2.01±1.15 1.60±1.00 1.91±1.00 1.30±0.74 2.21±1.86 1.39±0.88 1.75±1.04 2.27±1.21 
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Table 6.3.1.2. Percent reduction in metabolic parameters Pre- and Post-surgery. 
 
                                                           % Reduction (min, max) 
     All    Gastric banding  SG   BPD 
BMI (Kg/m
2
)    12.37 (3.68, 19.09)  11.36 (4.63, 18.55) 10.76 (4.28, 16.49) 16.96 (14.41, 19.09) 
Fasting blood Glucose (mmol/L) 18.32 (-52.86, 50.00)  25.24 (14.29, 42.16) 17.50 (-17.31, 50.00) 14.91 (-52.86, 50.00) 
Insulin     36.69 (-13.66, 100.00)  32.98 (-9.52, 59.09) 30.31 (-13.66, 68.75) 44.79 (5.17, 79.69)  
HOMA IR    49.88 (-29.88, 100.00)  50.44 (8.91, 67.04) 40.94 (-29.88, 79.41) 62.49 (41.81, 83.72) 
Triglycerides     11.81 (-72.93, 67.37)  28.54 (-3.88, 65.87) 12.42 (-25.93, 67.37) -7.64 (-72.93, 36.70)  
Total cholesterol (mmol/L)  11.20 (-26.84, 39.79)  8.03 (-26.84, 30.95) 3.13 (-23.91, 13.03) 25.26 (15.98, 39.79) 
LDL cholesterol (mmol/L)  5.91 (-87.79, 51.20)  0.28 (-87.79, 47.34) -7.32 (-65.35, 27.84) 30.98 (17.24, 51.20) 
HDL cholesterol (mmol/L)  3.19 (-34.06, 37.96)  -3.57 (-26.58, 7.48) -4.30 (-34.06, 17.68) 22.33 (7.04, 37.96)  
HDL/LDL  ratio   -10.52 (-121.86, 41.83)  -15.85 (-121.86, 32.59) -2.87 (-85.78, 41.83) -16.23 (-90.47, 9.06) 
TG/HDL ratio    3.16 (-111.36, 72.09)  29.59 (-3.88, 67.11) 12.25 (-50.80, 72.09) -40.13 (-111.36, 10.44)   
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6.3.2 Bariatric surgery modulated inflammatory state in adipose tissue.  
6.3.2.1 The change in TLRs expression following bariatric surgery 
 Comparison of pre- versus post-surgery highlighted that TLR4 mRNA 
(P<0.01) and TLR2 (P<0.05) were significantly reduced in AbdSc AT when 
analysed by student paired-t test. However the reduction of mRNA and protein 
expression did not appeared to be influenced by the different surgery type when 
controlled for BMI. 
                
 
 
Fig 6.3.2.1. The comparison of (A) TLR4 expression and (B) TLR2 mRNA levels pre versus 
post surgery. Sub-division of (C) TLR4 mRNA and (D) TLR2 mRNA by surgery type. Data 
are represented as 1/normalized expression (target protein intensity normalized to β actin in 
the same sample target gene or Ct value normalized to 18s gene in the same sample).   
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6.3.2.2 Reduction of IL-6 and NFB signaling molecule post-bariatric surgery. 
 Phosphorylated NFB protein expression (P<0.05) in AbdSc AT taken from 
patients who underwent to bariatric surgery were observed. IL-6 mRNA levels were 
also shown to decrease post surgery (P<0.05). However again the mRNA reduction 
following surgery for NFB and IL6 were not altered significantly by surgery type. 
                        
 
  
                           
                         
 
   
 
Fig 6.3.2.2.  The comparison of (A) phosphorylated NFB protein expression, (B) western blot of 
phosphorylated NFB protein and (C) IL-6 mRNA levels pre versus post surgery. Sub-division 
of (D) NFB protein expression and (E) IL-6 mRNA by surgery type. Data are represented as 
1/normalized expression (target protein intensity normalized to β actin in the same sample target gene 
or Ct value normalized to 18s gene in the same sample).   
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6.3.2.3 Reduction of adiponectin and IB signaling molecule post-bariatric 
surgery. 
 Adiponectin mRNA level (P<0.001) were reduced in AbdSc AT taken from 
patients who underwent bariatric surgery which was also observed for IB (P<0.05). 
The reduction in the noted gene expressions was similar across bariatric surgery 
types (Figure 6.3.2.3). 
                                  
    
 
Fig 6.3.2.3.  The comparison of (A) Adiponectin expression and (B) IB mRNA levels 
pre versus post surgery. Sub-division of (C) Adiponectin mRNA and (D) IB mRNA by 
surgery type. Data are represented as 1/normalized expression (target protein intensity 
normalized to β actin in the same sample target gene or Ct value normalized to 18s gene in 
the same sample).   
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6.3.3 Independent correlation of TLR4 expression and NFB signalling 
molecules in AT post-surgery.  
 There were no observed correlations between the expression of TLR4, IL6, 
NFB and TRAF6 in AT either pre- or post-surgery (Fig 6.3.3.1). Strong correlation 
between TLR4 and TLR2 were observed in both pre- and post-surgery (Pre-surgery 
r=0.890, P<0.001; Post surgery r=0.866, P<0.001). However there was a negative 
correlation observed between NFB and adiponectin prior to surgery (r= -0.567, 
P=0.002). In addition post-surgery, there was a positive correlation noted between 
TLR4 and adiponectin (r=0.545, P=0.003), IB (r=0.529, P=0.003), the NFB 
inhibitory factor and TLR2.  
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6.3.4 The associated changes in triglyceride levels and TLR4 mRNA reduction 
pre- versus post-surgery. 
 The triglyceride (TG) levels were split into quartiles, noting that when all 
subjects were grouped together, the third quartile (Q3) showed the greatest drop of 
serum TG (55.5% reduction post-surgery (P<0.001)) which was also associated with 
a significant reduction in TLR4 mRNA expression (P<0.001; Fig 6.3.4.1).  
   
 
Fig 6.3.4.1 Changes in mRNA level of TLR4 in AbdSc AT and serum 
triglyceride. mRNA level of TLR4 data are represented as 1/∆dCt. Delta change in 
triglyceride level (serum triglyceride before surgery – serum triglyceride after 
surgery) of each subject was calculated. Sub-groups were divided into quartiles 
according to delta changes in triglyceride level. First quartile (Q1) was the lowest 
25% of serum triglyceride delta change while the third (Q3) was the highest 25% of 
triglyceride delta change. Second quartile was the delta changes that were in between 
Q3 and Q1.  
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6.3.5 Triglyceride rich lipoprotein, VLDL, induced TLR4 expression in 
differentiated human adipocytes. 
 The differentiated human adipocyte cell line, Chub S7, were treated with 
triglyceride rich lipoprotein or VLDL over a 24 hr period. The effect of these lipids 
on TLR4 mRNA expression highlighted that there was a dose dependent increase in 
TLR4 mRNA expression (Figure 6.3.5.1). 
 
 
Figure 6.3.5.1. Effects of VLDL on TLR4 expression. Differentiated Chub-S7 
adipocytes were treated with 0, 5, 25, 50 and 100 ug/mL for 24 hr. Phosphate buffer 
saline containing 0.34 mM EDTA was used as control. The TLR4 mRNA level was 
measured by RT-PCR. The data were normalized to 18S mRNA level. The 
difference in expression was assessed by two way ANOVA test; ***, P<0.001, each 
concentration vs. control cells) 
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6.4 Discussion 
In this study, the improvement of fasting blood glucose, insulin, triglyceride, 
total cholesterol and LDL cholesterol post-bariatric surgery were observed. Although 
the degree of reduction did not appear to relate to the surgical intervention used. 
Whilst weight loss was clearly observed over time due to the bariatric surgery, all 
patients still remained classed as obese although there was metabolic improvements 
and significant changes noted in adipose tissue inflammation. As such this study 
cohort provided a unique model to study the molecules or pathways that might be 
involved in resolving inflammation in adipose tissue which may be coupled with 
systemic metabolic improvement independent of significant weight loss. 
The similar findings also showed the improvement of metabolic and 
inflammatory state in patients was surgery type independence (Fenske et al., 2013). 
However, laparoscopic Roux-en-Y gastric bypass has been recently reported higher 
improvement of BMI, circulation insulin and total cholesterol compare to 
laparoscopic sleeve gastrectomy after one year surgery (Iannelli et al., 2013). After 2 
years surgery, patients underwent Roux-en-Y gastric bypass showed more fat loss 
than patients who underwent gastric banding (Trakhtenbroit et al.).  Differences in 
the findings of the effects of surgery type on BMI and metabolic markers could be 
contributed to weight loss, differences of baseline before surgery and duration after 
surgery. However, bariatric surgery clearly provides benefits to obese T2DM.    
Expression of TLRs in adipocyte has been reported (Brenner et al., 2012; 
Poulain-Godefroy et al., 2010). The TLRs signaling cascade is triggered by binding 
complexes between TLRs and its ligands, such as lipopolysaccarides and fatty acid. 
The downstream of activation is mainly through the NFB pathway which under 
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normal condition is inhibited by un-phosphorylated IB. Pro inflammation cytokines 
such as TNF can bind to its receptor and consequently phophorylate IB into the 
active form which release NFB. The active nuclear transcription factor, NFB, then 
translocate into nuclease and stimulate pro-inflammatory cytokines expression 
(Fresno, Alvarez, & Cuesta, 2011). Expanding adipose tissue induced by high-fat 
diet induced the expression TLRs, resulting in activation of NFB and MyD88 in 
mouse model (S. J. Kim et al., 2012). In this study, the expression of TLRs and 
NFB signaling molecules in AbdSc AT taken from obese T2DM human subjects 
were evaluated.  The reduction of pro-inflammatory makers, TLR4, TLR2, IL-6 and 
NFB were observed after 6 months surgery, indicating the decline of inflammation 
in adipose tissue. However, there was no correlation between TLR4 expression and 
NFB signalling molecules such as TRAF6 and NFB itself, suggesting that NFB 
was regulated by others pathway such as MAPK which mainly involved in insulin 
resistance signalling pathway. 
Surprisingly, the reduction of anti-inflammatory markers such as adiponectin, 
IB and IL-10, expression in adipose tissue were also observed. In contrast, previous 
studies showed the increase of circulating adiponectin after surgery. As mentioned 
above, there were some differences in weight loss, duration after surgery and patient 
characteristic baseline. The reduction of anti-inflammatory mediated molecules could 
be interrelated with the regulation of inflammatory response. In lean, adiponectin 
showed the positive correlation with inflammatory cytokines such as IL-6 and TNF 
in order to protect the cells from uncontrollable inflammation, whilst, in obese 
T2DM, adiponectin was reduced and some studies showed the negative correlation 
with those inflammatory cytokines, indicating the uncontrollable inflammation in 
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obese T2DM. In this study, the negative correlation between adiponectin and NFB 
was observed before surgery but after weight loss induced by bariatric surgery, there 
was no association between adiponectin and NFB, demonstrating that adipose tissue 
become recover from uncontrollable inflammation. The further experiments studying 
the long term effects of bariatric surgery and kinetic changes of inflammation are 
required to verify the conclusion.  
Because fatty acid can bind to TLR4, it is interesting to study how the 
reduction of lipid profiles after surgery associate with TLR4 in adipose tissue. In 
vitro study, primary human adipocyte treated with saturated fatty acid and high 
glucose increased the protein level of TLR4, indicating that TLR4 play at least in 
part of a long term inflammation in adipose tissue. 
Thus, delta changes between pre- and post-surgery of serum triglyceride of 
each subject were calculated and put the data in order. Subjects were divided into 
three qualities according how well serum triglyceride was reduced. All subjects in 
the 3th quartile which were the first 25% of subjects whom circulating triglyride 
were reduced better than the others 75% of subjects showed the reduction of TLR4 
expression, indicating that triglyceride was the factor that influenced TLR4 
expression in adipose tissue. 
Moreover, human differentiated adipocyte cells were treated with different 
concentration of triglyceride rich lipoprotein, VLDL. VLDL was used in this 
experiment because of limitation of triglyceride solubility and its mimic to the 
majority form of triglyceride in circulation. The expression of TLR4 was induced by 
VLDL in a dose dependent manner, confirming the in vivo finding.  
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Taken together, there is a reduction in AT inflammation as denoted by TLR 
and NFB expression. The reduction in AT inflammation appears dependent on how 
successfully subjects reduce their serum triglyceride, which is supported by in vitro 
studies. These studies suggest that bariatric surgery lead to metabolic improvement 
with weight loss, whilst dietary intervention is still required to ensure triglyceride to 
reduce inflammation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CHAPTER 7 : Discussion 
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7.1. Discussion 
 Whilst it is clear that increasing adiposity contributes to increased health risk 
our understanding of the multiple mechanisms where by adipose dysfunction can 
contribute to the increased risk of T2DM and CVD remains in its infancy. Part of the 
challenge to determine the mediators of this disease risk is the multiple factors that 
appear to be involved at any one time that may contribute to this risk, either from 
dietary sources, systemic patient profiles and how adipose tissue may function within 
this complex environment. Recent studies have highlighted that beyond glycaemic 
control, subjects with T2DM and CVD appear to be exposed to long-term sub-
clinical inflammation which appears to exacerbate their metabolic condition over 
time. As such this thesis sought to evaluate the potential mediators of sub-clinical 
inflammation, principally focusing on the role of systemic lipids and the mechanisms 
of sub-clinical inflammation derived from adipose tissue and the adipocyte.  
This thesis therefore examined the role of lipoprotein-associated 
phospholipase A2 (LpPLA2) a member of the phospholipase A2 super family of 
enzymes and its isoforms which has been shown to generate Ox-LDL, other pro-
inflammatory mediators, such as lysophosphatidylcholine and oxidised fatty acids 
(Rosenson & Stafforini, 2012; Toth et al., 2010; Zalewski et al., 2006). The rationale 
behind this arose as LpPLA2 derived from macrophages and foam cells and has been 
shown to be up-regulated in conditions of inflammation such as CVD (Khakpour & 
Frishman, 2009; Kinney et al., 2011; Oei et al., 2005; Winkler et al., 2007), whilst 
studies on LpPLA2 and isoforms in adipocytes were absent, despite their clear 
similarities between the two cell types. The studies in this thesis principally 
highlighted that there was an association between circulating Ox-LDL and LpPLA2 
  
134 
 
which appeared to be related to adiposity and diabetic status. Further in vitro findings 
determined that LpPLA2 appeared to support the interconversion of LDL into Ox-
LDL through the use of the adipocyte, since blockade of LpPLA2 signalling within 
the adipocyte partially blocked Ox-LDL production. Clinically this is relevant as 
previous studies have shown that association between Ox-LDL production and 
weight gain but the mechanisms of LDL modification in foam cells remain unclear 
(Maria Waegner et al., 2011; Nelson et al., 2012; Vickers et al., 2009; Wang et al., 
2010; Yang et al., 2010). These studies however highlighted, in a controlled in vitro 
system, that the adipocyte could act as another source of Ox-LDL production, 
suggesting LpPLA2 could be targeted in adipose tissue to reduce systemic Ox-LDL 
production. Clearly, recent studies with the LpPLA2 inhibitor, Darapladib, have 
shown that this medication be an effective treatment for lowering CAD disease in 
unstable foam cell plaques (Johnson et al, 2014; Dave et al, 2014). As such the 
inhibitor may therefore be effective for targeting adipose tissue due to the similarities 
between cell types. Further it appears LpPLA2 enzymatic activity is critical for 
eliciting macrophage responses associated with a variety of inflammatory processes 
and signalling pathways such as c-Jun-kinase (JNK) so many have other downstream 
effects (Tzang et al, 2009).  
Interestingly serum LpPLA2 had a number of positive correlation with 
cholesterol, triglycerides, LDL and Ox-LDL as might be anticipated but previous 
studies had apparently never examined the adipocyte as an active source of LpPLA2 
signalling with the LpPLA2 protein expression raised in conditions of T2DM and 
may actively contribute to the Ox-LDL observed in in vivo studies, with recent 
studies confirming this and LpPLA2 acting as a potential predictive biomarker of 
T2DM risk (Maria Waegner et al., 2011; Nelson et al., 2012). In fact the current 
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thesis studies identified that despite controlling for BMI the positive correlation of 
circulating LpPLA2 with cholesterol, LDL or Ox-LDL across the combined cohort, 
or within the T2DM cohort was maintained suggesting the systemic lipid profile 
appears important (Sanchez-Quesada et al., 2012).    
 To examine the potential impact of lipids beyond the confines of LpPLA2 
subsequent studies were undertaken to examine the relationship between systemic 
lipids and their association on the innate immune cascade in AT taken from patients 
before and following bariatric surgery. These studies highlighted that weight 
reduction had a significant impact on reducing the innate immune intracellular 
signalling cascade as well as systemic metabolic improvement which appeared to be 
irrespective of surgical intervention used which a previous in vivo study had noted as 
well (Fenske et al., 2013). However the success in reducing the subject’s 
inflammation, as noted via assessing the key receptor of the innate immune pathway, 
the TLRs, appeared to be linked to how their systemic triglyceride levels dropped 
post-surgery as well. Furthermore additional in vitro studies identified the 
inflammatory nature of systemic lipids on the adipocyte, again highlighting the 
importance of the cell in sub-clinical inflammation.     
Taken together these current in vivo and in vitro studies highlight the 
importance of systemic lipids to potentially influence local adipocyte function and 
regulation. Further that whilst human studies are critical to determine the mediators 
of increased health risk this needs to be coupled with both longitudinal studies and in 
vitro analysis to identify potential therapeutic targets as well as lifestyle intervention 
targets, particularly in reference to systemic lipids.    
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7.2 Limitations  
 Some of the details of the limitations have in part been discussed in the 
relevant chapters however it is important to note that all the subjects that took part in 
these studies were women. Whilst this could be viewed as strength and would have 
reduced the potential confounding factors that could arise through assessing two 
genders, within the same sample size obtained, it also means the analysis may only 
be applicable to women. Women were chosen for several reasons, including high 
attendance at clinical and follow up, willingness to engage more effectively with 
clinical research studies, willingness to have fat biopsies taken either during surgery 
or through needle biopsy post-surgery.   Subsequent studies could repeat the current 
studies in men, which would potentially highlight similar findings but show men 
have a higher inflammatory risk which is coupled to their raised metabolic risk 
compared to women.  
Human adipose tissue appears critical in the arising systemic inflammatory 
response and the inflammatory gene expression clearly changed over a 6 month 
period when assessing the subjects undergoing bariatric surgery. However a 
limitation in this study was that there were no adipose tissue biopsies taken within 
the first few days post-surgery, when the subjects appeared to reverse their T2DM 
status and improve their metabolic health. It would have been interesting to 
determine whether this lead to a significant reduction in the inflammatory response 
from adipose tissue and whether the type of surgery influenced that response. Also it 
would been interesting to increase the cohort size to try to evaluate the influence of 
medication pre and post-surgery on the subjects undergoing bariatric surgery but due 
to small sample size there was not attainable. Nevertheless, these current studies 
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have given a valuable insight into the role of lipids and the function of adipose tissue 
in understanding the inflammatory response in metabolic disease. 
7.3. Future directions 
 This thesis shows the first evidence identifying that the mediators of sub-
clinical inflammation such as systemic lipids can activate multiple concurrent 
mechanisms to increase metabolic disease risk.  Further analysis of LpPLA2 and its 
isoforms in the peripheral metabolic and inflammatory pathways may also ascertain 
how these enzymes may change their functions to be more pro-anti-inflammatory 
and when and how this may occur. As such further studies would need to address 
how knock-down of LpPLA2 and its isoforms may affect adipocyte cell function and 
production of both pro- and anti-inflammatory cytokines. Also the current clinical 
use of an LpPLA2 inhibitor in CAD provides potential opportunities to understand 
the influence of such a drug on Ox-LDL production derived from adipose tissue 
which may also support to lower CAD and T2DM risk. The use of studies to 
examine the arteriovenous differences across human adipose from subjects in 
different metabolic states, with and without an LpPLA2 inhibitor may allow the 
assessment of how Ox-LDL and other pro-inflammatory cytokines may reduce with 
such an intervention. This may further highlight the potential in vivo importance of 
an LpPLA2 inhibitor on adipose tissue.    
 Further future studies could also explore other lipid factors on adipose tissue 
metabolism to identify how these factors may influence the innate immune cascade. 
Specifically studies undertaking low fat diet intervention studies coupled with AT 
biopsies measurement pre- and post-intervention to ascertain what impact this may 
make on systemic lipids as well as the inflammatory status of the adipocyte ex vivo 
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and in vitro. The in vitro studies could study how pre-and post-intervention the 
adipocyte handles various factors such as TG, FFAs, LDL, HDL and VLDL to see 
whether a suitable weight loss diet can change the potentially pathogenic nature of 
the adipocyte observed in obese conditions. 
7.4. Conclusion 
 These studies have highlighted that the role and function of the adipocyte is 
complex and that there are many features and mechanisms of the adipocyte still to be 
explored. Despite the apparent lipid storage capacity of the adipocyte the adipocyte is 
a complex cell with multiple interactions vital to human physiology which makes 
adipocyte dysfunction in obese and diabetic conditions more problematic to resolve. 
However these current studies have shown the vital importance of systemic lipids 
control to reduce the pathogenic nature of the adipocyte. Furthermore unless 
substantial weight loss drugs can be devised it will be important to ensure that in 
metabolic disease systemic lipids profiles are actively managed to reduce further 
complications that may be derived due to the inflammatory response of the 
adipocyte.      
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APPENDIX  
Solution and Buffers 
A.1 General cell culture solutions 
A.1.1 Lysis buffer  
Ammonium Chloride (NH4Cl) 0.154    mol/L 
Potassium Bicarbonate (KHCO3)  10    mmol.L 
Sterile water 
 
A.1.2 Collagenase 
Collagenase powder 10   mg 
Hank’s Buffer Salt solution 50   mL 
Pen/Strep   5   mL 
Sterile water  445   mL 
 
A1.3 Completed DMEM/F12 Phenol red free medium 
DMFM/F12 Phenol red free medium 500   mL 
Fetal Bovine Serum 50   mL 
Pen/Strep 5   mL 
Transferin 1   mL 
 
A2. Western Blot solution 
A2.1 4% Sodium dodecyl sulphate (4% SDS) 
SDS 4   g 
Water 100  mL  
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A2.2 Loading Buffer 
125 mM Tris-HCl, pH 6.8 625  µL 
4% SDS 200  µL 
Glycerol   1  mL 
Dithiothreitol 100  µL 
Bromphenol Blue 125  µL 
Distilled  water 250  µL 
 
A2.3 Phosphate Buffer Saline 
Na2HPO4  1.44  g 
KH2PO4 0.24  g 
NaCl 8.0  g 
KCl 0.2  9 
Sterile water 1000   mL 
Adjuste pH to 7.6    
 
A2.4 PBS-T 
PBS 1000  mL 
Tween 20 1  mL 
 
A2.5 Blocking reagent  
I-block powder 0.2  g 
PBS-T 100   mL  
 
 
A2.6 4% stacking gel (for 2 gels preparation)  
 
Distilled water 6.1   mL 
Acrylamide 1.3   mL 
Stacking buffer 2.5  mL 
10% APS 50  µL 
TEMED 10  µL 
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A 2.7 10% separating gel (for 2 gels preparation) 
 
Distilled water 7.8  mL 
Acrylamide 6.6  mL 
Resolving buffer 5.2  mL 
10%APS 200  µL 
TEMED 20  µL 
 
 
A 2.8 7.5% separating gel (for 2 gels preparation) 
 
Distilled water 9.4   mL 
Acrylamide 5.0  mL 
Resolving buffer 5.2  mL 
10% APS 100  µL 
TEMED 20  µL 
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